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Abstract
The Boron Neutron Capture Therapy (BNCT) treatment planning process of the Harvard/MIT team used
for their clinical Phase I trials is very time consuming. If BNCT proves to be a successful treatment, this
process must be made more efficient. Since the Monte Carlo treatment planning calculations were the
most time consuming aspect of the treatment planning process, requiring more than thirty six hours for
scoping calculations of three to five beams and final calculations for two beams, it was targeted for
improvement. Three approaches were used to reduce the calculation times. A statistical uncertainty
analysis was performed on doses rates and showed that a fewer number of particles could not be used and
still meet uncertainty requirements in the region of interest. Unused features were removed and
assumptions specific to the Harvard/MIT BNCT treatment planning calculations were hard wired into
MCNP by Los Alamos personnel, resulting in a thirty percent decrease in runtimes. MCNP was also
installed in parallel on the treatment planning computers, allowing a factor of improvement by roughly the
number of computers linked together in parallel. After theses enhancements were made, the final
executable, MCNPBNCT, was tested by comparing its calculated dose rates against the previously used
executable, MCNPNEHD. Since the dose rates in close agreement, MCNPBNCT was adopted. The final
runtime improvement to a single beam scoping run by linking the two 200MHz Pentium Pro computers
was to reduce the wall clock runtime from 2 hours thirty minutes to fifty nine minutes. It is anticipated that
the addition of ten 900 MHz CPUs will further reduce this calculation to three minutes, giving the medical
physicist or radiation oncologist the freedom to use an iterative approach to try different radiation beam
orientations to optimize treatment.
Additional aspects of the treatment planning process were improved. The previously unrecognized
phenomenon of peak dose movement during irradiation and its potential for overdosing the subject was
identified. A method of predicting its occurrence was developed to prevent this from occurring. The
calculated dose rate was also used to create dose volume histograms and volume averaged doses. These
data suggest an alternative method for categorizing the subjects, rather than by peak tissue dose.
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1. Introduction
Treatment planning is an integral yet time consuming part of the Harvard/MIT
Boron Neutron Capture Therapy (BNCT) Phase I clinical trials. If the clinical trials show
efficacy of this experimental treatment, and BNCT becomes a mainstream treatment, the
treatment planning must be streamlined. In chapter one of this thesis, the treatment
planning procedure is described, providing a written record for the reader. Chapters two,
three, and four contain the accomplishments of this thesis work. Chapter two details the
methods used to greatly reduce the computational time needed in treatment planning: a
voxel dose rate error analysis, modifications to the Monte Carlo computer code, and
implementation of parallel computing. Also described are the quality assurance tests used
to verify the code.
During this thesis research, a previously unrecognized phenomenon of peak dose
movement was identified as having occurred in several of the subject irradiations.
Further investigation shows a relation between slight subject overdoses and this
phenomenon. This effect was also investigated with relation to the beam geometry of the
treatment, either perpendicular or nearly parallel opposed. A method of predicting when
this global maximum movement occurs was developed. This phenomenon is described in
chapter four.
The retrospective dosimetry calculations for this thesis include dose volume
histograms and volume averaged doses. These new volume averaged doses could be used
as the basis for reorganizing the subject cohorts, rather than on the peak dose, as required
by the existing FDA-approved clinical protocol. Additional calculations produced the
difference between peak dose to tissue and peak brain dose. These results are described
in chapter five.
2. Harvard/MIT BNCT Treatment
Boron Neutron Capture Therapy (BNCT) was first suggested by Gordon Locher
in 1936'. Through the application of a boron containing pharmaceutical that is selectively
absorbed by a tumor, the tumor receives more dose than the surrounding tissue during
subsequent neutron irradiation2'3'4. The increase in dose is caused by the short range of
the alpha and 7Li reaction products from neutron absorption by a 'oB nucleus. This
process is currently being investigated by several teams around the globe in the treatment
of a variety of cancers5'6. The Beth Israel Deaconess Medical Center / MIT group is
currently engaged in Phase I clinical trials using the M.I.T. Nuclear Reactor Laboratory's
epithermal neutron beam to study the toxicity of neutron irradiation on neural tissue7' 8.
After the phase I study has been completed, it is hoped that a phase II study will show the
efficacy of BNCT for controlling Glioblastoma multiforme and metastatic melanoma.
2.1 Treatment Process
The BNCT treatment process includes a variety of steps in addition to the physical
irradiation of a subject. Beam characterization, treatment planning, online dosimetry,
and retrospective dosimetry are all parts of the BIDMC/MIT procedure. Each one of
these topics is described in detail in this chapter. Beam characterization is necessary to
ensure the proper dose is delivered during irradiation. Treatment planning optimizes the
radiation dose to tissue and tumor. Retrospective dosimetry verifies the proper dose was
delivered during the irradiation procedure and is used to correlate effects, such as tumor
regression or reoccurrence, or healthy tissue neurological effects, with delivered dose.
The MIT Nuclear Reactor Laboratory's current epithermal neutron beam, m67, is
characterized every six months9. The fast and thermal neutron and gamma dose rates are
measured at various depths of an ellipsoid head phantom. The 'lB dose rates are
calculated from the thermal neutron flux. The m67 beam is also equipped with two
thermal and epithermal neutron detectors, called the beam monitors. The dose rates are
proportional to the beam monitor count rates, which are monitored during subject
irradiation. After a calibration is completed, the first stage of the treatment process does
not occur until a human subject has been accepted into the protocol.
Treatment planning is the most time consuming aspect of the entire process,
taking a minimum of five days to complete even though the actual irradiation takes only a
few hours. The treatment planning software, MacNCTPlan, designed and developed at
Harvard/MIT, uses CT and MRI data to allow the medical physicist to specify the
location of tumor and normal neural tissue, construct a subject specific individual model
for radiation transport, and visualize dose rate data from the transport calculations' 1 1 '2 .
During the several days prior to the irradiation, the medical physicist compares the
dosimetric result of using different irradiation beam orientations and selects the final
beam geometry. Comparisons are based on dose to sensitive locations as well as
maximum, minimum, and dose-volume distributions to tumor and normal tissue. These
evaluations are based on calculated dose rates from Monte-Carlo simulation of the
irradiation. Once the final beam is selected, a more lengthy calculation is performed to
reduce the associated statistical error, since the resultant dose rates will be used to
determine the length of irradiation.
The Monte Carlo program MCNP1'3 is used to calculate the dose rates throughout
the head phantom and the subject for various beam orientations. MCNP is used for a
variety of reasons, including its ability to model the subject, represent the epithermal
neutron beam's energy and radial distributions and the complex thermalization process of
epithermal neutrons 4.
Once the final beam or beams are determined, there is a distinct change in the
dosimetry approach, instigated by the written directive of this Phase I protocol. No
longer are doses to various locations considered; only the maximum dose to tissue is
important, since the subjects are divided into cohorts on this basis. Since the dose
contribution from the 'OB reaction is roughly one quarter of the total dose to normal
tissue, an accurate dosimetry protocol must account for the subject 'oB biodistribution
during the time of irradiation. Accordingly, the blood 'oB concentration is measured with
inductively coupled plasma atomic emission spectrometry (ICP-AES) or prompt gamma
neutron activation analysis (PGNAA), and the total integral dose to the maximum dose
location is determined during irradiation. This calculation relates the beam monitor
readings to the dose rates in phantom and the Monte Carlo calculations of phantom and
subject dose rates.
After the irradiation is concluded and the final blood boron concentration curve is
determined through the least squares fit of the measured data with a double or triple
exponential, retrospective dosimetry focuses on the dose to a variety of locations and
volume dose, in addition to the maximum dose location. The average dose to neural
tissue, the maximum, minimum and average tumor doses are also of interest.
2.1.1 Beam Characterization
The neutron and gamma dose rates of the MIT Nuclear Reactor Laboratory's
epithermal beam are measured every six months with an ellipsoid head phantom 15' 1617
The 'OB component is calculated from the thermal neutron fluxes. The phantom is an
acrylic shell filled with water. It has several holes in the bottom, which allow the
insertion of a radiation detector. Mixed field dosimetry methods are used to determine
the magnitude of each dose component. A dual ion chamber is used to measure the fast
and gamma dose rates. The cadmium difference method is used to determine the thermal
neutron fluxes. The appropriate kerma factors are applied to determine the dose rates
from thermal neutrons and the boron capture reaction. All measurements are taken on the
central axis of the phantom at one centimeter intervals. The phantom is aligned with the
beam's axis and its apex is located one cm below the ceiling of the medical room. The
beam counters measure the neutron flux associated with each set of axial dose rate
measurements. The neutron flux varies proportionately with reactor power, which is
typically 4.8 MW during the phantom measurements and subject irradiation. The
immediate result of this measurement is the correlation of beam count rates with phantom
dose rates.
*MCNP is a trademark of the Regents of the University of California, Los Alamos National Laboratory
The axial dose rates in phantom are independently calculated by MCNP.
Although the dose rates to every 1 cm3 voxel within the 21 cm by 21 cm by 25 cm model
of the head phantom can be calculated, only the dose rates along the central axis are
compared to the experimental data. In a process similar to the modeling of the subject,
which is described later in this chapter, the phantom is modeled in MCNP as a water
ellipsoid with the air holes in the bottom where the detectors are inserted. Neutron and
photon dose rates are calculated for each cell. The boron dose is determined from the
thermal neutron flux in each cell.
Measured and MCNP calculated dose rates are then plotted as dose rate vs. depth,
as shown in Fig 2.1a-e. The fast neutron, thermal neutron and boron dose rates are
directly compared. MCNP calculates the dose rates from the structural gammas and
induced, or capture gammas, individually, which are compared to the measured gamma
dose rate, or the sum of the two.
Figs. 2.1 a-d show the adjusted MCNP phantom dose rates and experimental data
for the June 1997 characterization'8 .
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Using the dose rate vs. depth data, the least squares difference scaling factor is
then found. For the gamma component, a scaling factor for each MCNP dose rate is
used. These scaling factors physically account for the difference between experimental
dose rates and the calculated MCNP dose rates. With this correction factor, the doses
from MCNP can then be considered as the physical dose rates occurring in the subject.
Typical scaling factors, shown in Table 2.1, are near unity, indicating that there is a
strong agreement between dose rate calculations and measurements.
Table 2.1 Scaling Factors for the June 1997 Characterization
Thermal N Fast N '0B Induced y Structural y
0.824 1.088 0.805 0.901 1.810
2.1.2 Treatment Planning
Individualized subject treatment planning begins when a subject enters the
protocol. The major steps include MCNP simulation of the irradiation, relation of subject
and phantom MCNP dose rate results and calculation of anticipated irradiation time.
The introduction of individualized subject data begins with CT scans and MRIs.
These images allow the physician to localize potential tumors, as well as construct a
model using subject specific data. As with the phantom data, the images are imported
and processed as follows. Within MacNCTPlan, the images are thresholded to
differentiate air, soft tissue and bone, which are included in the model. Several potential
beam orientations are designated. MacNCTPlan also voxelizes the subject data into 1
cm3 cells. These data are converted into a MCNP input deck, and MCNP is run to
determine the dose rates in each voxel for each beam orientation. Each potential beam is
run so that its statistical error is on the order of five percent in the region of interest. One
or two final beams are chosen and they are run until the statistical error is around one
percent in the region of interest.
The dose rate scaling factors, created by the phantom calibration, are also applied
to the subject Monte Carlo data to obtain the representative physical dose rates
throughout the subject. The maximum physical dose rates in the phantom and subject are
then determined for anticipated boron concentrations, typically 15 and 12 ppm for the
first and second beams. The ratio of the maximum of the two dose rates is called the
Monte-Carlo Dose Rate Ratio (MCDRR). When the peak dose rate measured in phantom
during the axial irradiation is divided by the MCDRR, the result is the physically
occurring peak dose rate in the subject from a specific, non axial, radiation beam
orientation. Although the MCDRR relates physical dose rates, it is based on the
calculated dose rates and the scaling factors, and hence will vary with the curve fit used.
Since the MCDRR is a ratio of the dose rates, small fluctuations in scaling factors will
have no significant impact on the MCDRR value.
After the final dose rates have been determined, the length of irradiation is
estimated. For one beam irradiations, the prescription dose is divided by the maximum
dose rate occurring in the subject, or the MCDRR times the maximum phantom dose rate.
For a dual beam irradiation, the process is more complex. Using MacNCTPlan, the dose
rates from both beams are added, assuming some neutron fluence weighting factor
between the first and second beam, as described in section 2.2.5. Once the dose rate
distributions of both the beams are added, the maximum dose rate location is calculated.
The ratio between a beam's maximum dose rate to the combined global maximum dose
rate is calculated. Using this ratio, which accounts for the beam weighting, and the
prescription combined global maximum dose, the target dose from each beam is
calculated for that beam's peak dose. During the irradiation the beam's peak dose is
determined by the count rates and boron biodistribution as described in the following
section.
2.1.3 Irradiation Procedure
The current protocol used by the BNCT group defines the intended target dose,
the prescription dose, as the maximum dose occurring within any non-tumor tissue. The
maximum dose location will vary with number and orientation of beams, and can occur in
scalp, skull or brain. This prescription dose is incrementally increased by ten percent
with each new cohort. The previous dose steps have been 880, 990, 1065 RBE cGy.
At various times throughout the infusion and irradiation, 1 ml blood samples are
taken to determine the boron concentration. These samples are analyzed with either
inductively coupled plasma atomic emission spectrometry or prompt gamma neutron
activation analysis 9' 20 . The resulting biodistribution curve is fit with a double or triple
exponential.
To ensure the best calculation of subject dose, the cumulative dose is recalculated
as the subject's biodistribution curve is measured. There are two methods currently used
by the group. The method developed by Dr. Guido Solares allows almost instantaneous
dose calculations and evaluations 21'22. His computer is taking continuous readings from
the beam counters. The second method developed by the group is slightly more discrete.
The "laptop" calculations recalculate the cumulative dose to the subject every fifteen
minutes, and more frequently near the end of irradiation. These calculations account for
the subject's boron biodistribution curve and the effective power of the reactor.
The beam monitors measure the neutron rates and are a direct reflection of reactor
power. Reactor power will vary throughout the irradiation, during startup, shutdown and
subject repositioning. This variation affects dose rates and the delivered dose during the
irradiation. By dividing the beam monitor measurements during subject irradiation by
measurements during the phantom irradiation, the effective reactor power is found over a
given time interval. When this ratio is divided by the MCDRR, multiplied by the
measured phantom dose rates and a particular time interval, the peak dose delivered by
the non-boron components to the subject is calculated. The associated boron dose is
multiplied by the average boron concentration during the time interval.
The effective reactor power is used to calculate the effective full power irradiation
times and the effective boron concentration for each beam after the irradiation is
concluded. These two post irradiation quantities will be used to calculate the
retrospective doses from the Monte Carlo dose rates.
2.1.4 Laptop Retrospective Dosimetry23
The effective irradiation time for each beam is a measure of full power irradiation
time, and is multiplied by the calculated dose rates, scaling factors, and boron
concentration to find the delivered dose to any location within the subject model.
Equation 2.1 shows that for a dual beam irradiation, the delivered dose to the ith voxel is
the sum over the two applied beams, B 1 and B2, of the dose rates multiplied by their
respective effective irradiation times.
Dose(i) = DR(i),, B TBI + DR(i)B2 TB2 Equation 2.1
The dose rate, DR(i), in equation one includes the boron dose rate component,
which should be multiplied by the beam's effective boron concentration. The effective
boron concentration for the first beam, BBEf , is the power weighted time averaged 'oB
concentration during a given beam. It is calculated using equation 2.2, where a and b are
the beginning and end of the irradiation beam, B(t) is the boron concentration as defined
by the final boron biodistribution curve, which includes 'oB concentration measurements
several hours after the irradiation has concluded. PEff(t) is the effective power. The other
beams are calculated in the same way.
b
B(t )  PEf (t) - dt
BER (ppm) = b Equation 2.2
Pfp(t) - dt
The biodistribution curve, along with the two physical parameters of actual
irradiation times and reactor power, are fixed and will not change with dose
recalculations, nor will the effective boron concentrations and irradiation times. The post
-irradiation values are used by MacNCTPlan in calculating a new MCDRR, which is then
used to recalculate the peak dose delivered to the subject in the laptop dosimetry
spreadsheet. Since the dose is based on measured values, the retrospective laptop dose is
the best estimate of the peak dose delivered.
2.1.5 MCNP Retrospective Dosimetry
Although the phantom measurement based dosimetry provides an accurate peak
dose in the phantom, it fails to determine the subject's final dose distribution, which has
important clinical significance. While the calculated dose rates are the only current
method of determining off axis dose rates, they do rely on the least squares fit of the
scaling factors. In cases where the measured and calculated values differ, it is possible to
use the calculated dose distributions and infer that the supposed peak dose was
significantly higher than was actually delivered. Figure 2.lb shows the calculated fast
neutron dose rate at 1 cm is fifteen percent higher than the measured dose rate. However,
since the least squares fit is applied over the entire curve, the volumetric dosimetry is a
reasonable approximation.
In the retrospective analysis, the doses to tumor and tissue are determined in
addition to the maximum dose. Within MacNCTPlan, the neural tissue can be identified
and marked in the same manner as the tumor. The volume of neural tissue for each voxel
can be determined, as can the total volume of neural tissue in the head. The volumes
calculated have been slightly higher than the anticipated values based on ICRP, but tend
to agree well with a newly constructed phantom model adopted by the MIRD
comittee 24 25. Once the volumes of tumor and tissue have been calculated, their
corresponding dose distributions can be used for volumetric dosimetry.
The retrospective doses to various locations are determined differently. The peak
or prescription dose is best determined with the laptop dosimetry, while average doses
can only be determined with MCNP. Calculation of the volume averaged doses requires
knowledge of the three dimensional dose distributions, which is only gained from the
MCNP calculations. Currently the depth vs. dose rate distribution along the beam's axis
only is obtained from phantom measurements.
Using the dose to each voxel and the fraction of each voxel that is either tumor or
tissue, it is possible to calculate the volume of tissue or tumor that receives a certain
amount of dose or higher. This plot is referred to as a dose volume histogram, or DVH.
DVHs are used by radiologists to visually determine the advantage dose, or the
additional dose the tumor receives to that of normal tissue. Dose volume histograms, in
low dose ranges, show the effects of beam geometry, with subjects with parallel opposed
beams having significantly higher volume doses than subjects with single or orthogonal
beams. In high dose regions, the x intercept, or peak dose, is a function of the
prescription dose.
2.2 Treatment Planning Process
The objective of treatment planning is to provide a timely method for determining
the best overall RBE dose distribution to healthy tissue and tumor. For healthy tissue,
the maximum dose rate and dose rates to sensitive structures are considered. For the
tumor, increased o1 B concentrations and RBE's may be accounted for in calculating the
minimum dose rate. Both the tumor and normal tissue dose distributions will vary with
the orientation of the neutron beam or beams. The treatment planning software,
MacNCTPlan developed at Harvard and MIT, allows these dose rate distributions from
single beams or combinations of beams to be compared. To achieve this end result,
several tasks must be completed. In part one of MacNCTPlan, CT and MRI images of
the subject are used, after processing and registration, to localize the tumor and generate a
model of the subject. MCNP calculates dose rates throughout this model. In part two of
MacNCTPlan, the dose rates are then visualized as isodose contours superimposed over
the CT or MRI images. This allows the medical physicist to evaluate different beam
orientations.
2.2.1. Preparation
The acquisition of subject CT and MRI scans is the first part of the treatment
planning process. In a single image series, about one hundred thirty images of parallel
planes two millimeter apart are collected. Image acquisition is done such that planes start
in the air located above the head and finish near the superior portion of the shoulders.
Each pixel in a CT image is represented by sixteen bits, but the image contains only 12
bits of information. The twelve bit Hounsfield numbers indicate the attenuation
coefficients in the individual. The Hounsfield number is simply an integer ranging from -
1024 to 4096. A single CT image file is a listing of each pixels' Hounsfield number in
addition to a file header. Each CT image is 512 pixels wide by 512 pixels tall. The MRI
images are also sixteen bit images, but are 256 by 256 pixels. These files are obtained
with proprietary medical systems, such as the GE or Siemens scanners at the BIDMC, but
are transferred to the Harvard/MIT BNCT Macintosh computers using the DICOM
protocol.
For both imaging modalities, at least two series are obtained: one with contrast (+)
and one without (-). The contrast agents, containing Iodine (I) and Gadolinium (Gd), are
used for CT and MRI, respectively. These contrast agents cause the subject's edema and
tumor to be more visible in the computer images. While the four image sequences, I+, I-,
Gd+ and Gd-, are available, not all of them are used, particularly if the tumor and edema
are visible with CTs.
Before they can be used in MacNCTPlan, the CT and MRI images must first be
processed. The files are first transferred to a Macintosh computer, using the DICOM
protocol. All the files are then imported using the public domain program, NIH Image.
NIH Image reads the actual data, but not the header. By subtracting the number of bytes
the data occupy from the file size, the header size can be determined. The CT data
occupy 16 bits times the image size, 512 by 512 for a total of 524,288 bytes. Using file
menu command import, the header size is entered and the file is imported as raw data.
This importing process automatically coverts the 16 bit images to 8 bit, with a
spectrum of 256 pixel intensities. This mapping can compress all available 12 bit
intensities, into 8 bit intensities, or a specific range of intensities, for example 1000 to
2048, can be mapped onto the intensity range, as illustrated in figure 2.2.
16 bit - 8 Bit 16 bit - 8 Bit
Figure 2.2 Mapping 16 bit images into 8 bit images.
The image mapping on the left will produce an 8 bit image that contains the entire 16 bit domain. The
image mapping on the right will produce an 8 bit image that contains only a specified domain of pixel
intensities.
Figure 2.3 shows the same CT image with and without this subrange specified.
Figure 2.3 I+ Imported Images. The image on the left represents a subrange of all pixel intensities, while
the image on the right is a complete mapping of all intensities. These images are 256 bit by 256 bit.
It can be seen that this subrange specification is thresholding the image. Since
several of the unwanted artifacts, such as those produced by towels, have very low
intensities, this thresholding reduces the amount of image processing and "cleaning" that
must be done.
The final conversion step is to reduce the CT stack to 256 by 256. This size
reduction is completed with the NIH Image scale command, where both the x and y
directions are scaled by 0.5. The image intensities are then inverted, or subtracted from
256. The resulting stack is then saved in the TIF file format.
Once all image files have been imported and converted into a single stack, the
artifacts are removed. The head holder, towels, and other external objects are removed in
each slice. The eraser tool can be used to remove them manually, or the magic wand
thresholding tool can select a contiguous body in each slice, such as the cross section of
the head, which is then copied on to a new 256 by 256 window. If the subject has metal
fillings, there will be several planes that contain shadows. These planes are replaced by
the nearest usable plane. Although this will cause the model to be unrepresentative of the
subject, this approximation is made in a region far from the beam entrance location and
will negligibly affect the dose to the region of the tumor and upper skull. After being
cleaned, the stack is saved as a TIF file. Figure 2.4 shows two images, the first showing
the shadows associated with metal fillings, the second showing the best replacement
image. These images also show the head holder and towels clearly.
Figure 2.4 Metal Filling Artifacts and Replacement.
Occasionally, the tumor is plainly visible from the I+ stack. Since the I+ and I-
stacks are typically acquired with the subject in the same position, the images are already
aligned. Since the tumor is visible in the aligned I+ stack, the time consuming
registration of the MRI and CT stacks becomes less necessary for treatment planning.
More often, however, the tumor is only clearly visible from the Gd+ images. Since the
subject model construction uses the I- images to avoid thresholding problems described
later, the Gd+ stack must be aligned with the I- stack. Each plane in the Gd+ MRI stack is
made to correspond to the I- CT plane with the same physical characteristics. For
example, the fourth plane in the CT stack, corresponding to a plane eight millimeters
from the top of the head, perpendicular to the central axis, is the fourth plane in the MRI
stack and exhibits the same physical features. Unfortunately, since the head is typically
in different orientations during scans, the Gd+ stack must be translated, scaled, and
rotated, often in two dimensions. Image registration is not a trivial task and is the subject
of ongoing research. To aid the process, the subject wears a latex swim cap with several
fiducial markers, in this case Vitamin E tablets, that are easily visible in both imaging
modalities. Fig 2.5 show I-, I+ images and their corresponding Gd+ image with fiducial
markers.
Figure 2.5 I-, I+, Gd+ Images of the same plane with fiducial markers. The tumor is in the upper left of
each image. The images have been mapped with different ranges.
2.2.2 MacNCTPlan Part I
In the first phase of MacNCTPlan, preparations for transport calculations are
made. The subject's CT and MRI scans are used to determine the tumor's location.
Based on the tumor's location and the medical physicist's experience with previous dose
distributions, three to five potential 3-D beam orientations are determined. The CT
images are used to construct a model of the target region, i.e. the subject's head, or other
body part. Discrimination between bone, air and soft tissue is determined from the
Hounsfield numbers of the CT image. The stack of CT images is divided into a lattice of
11,025 one cm3 cells. The fraction of air, tissue, tumor and bone, is determined to the
nearest twenty percent in each cell. This information, in addition to estimated boron
concentrations in tissue and tumor, is then used in constructing an MCNP input deck.
While there are additional steps within MacNCTPlan Part 1, only the ones significant to
model construction will be described.'
After the Gd+ files have been opened in MacNCTPlan, the tumor localization
(outlining) is directed by the physician. For each slice, the tumor is defined (outlined) by
drawing a line around it. This line defines a region of interest, or ROI. When all of the
tumor has been outlined, the ROI is saved in a separate file to be used with the I- stack.
When this step is completed, the I- stack is opened and used for the remaining
MacNCTPlan Part I procedures. The screen shot of MacNCTPlan in figure 2.6 shows the
tumor localization.
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Figure 2.6 Screen Shot of MacNCTPlan Tumor Outlining
The next step within MacNCTPlan is to differentiate air, bone and soft tissue by
thresholding the pixel intensities. Since the images were inverted, the air is colored white
due to its low image intensities, while the bone is dark at high image intensities.
MacNCTPlan allows the user to adjust the pixel intensity threshold for any slice and
color the corresponding air, tissue or bone blue, green or red respectively. The coloration
allows visual feedback as the threshold is changed. Figures 2.7 is a MacNCTPlan screen
shot showing the thresholding step in MacNCTPlan. The reason that the I- stack is used
now becomes obvious. The I+ stack, if thresholded, would contain bone in locations that
it does not exist. The MRI stack does not lend itself to thresholding, since the bone and
air are similar in intensity. Even if the image is inverted and the air is artificially colored
white, the thresholding problem is even worse than in the I+ stack.
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The next significant step after thresholding is the determination of irradiation
beam orientations. The medical physicist uses his experience of dose distributions to
determine three to five possible beams. Deep tumors usually receive a bilateral
irradiation to increase dose to regions that would have low dose contributions from the
first beam. To precisely define the exact entrance and exit locations of the beams, the
stack is manipulated in three dimensions, allowing two cross hairs to be placed at the
preferred entrance location. To guide the medical physicist, the irradiation beam's central
axis and edges are displayed superimposed over the reconstructed CT images of two
Slice 62
orthogonal planes along the central beam axis. Figure 2.8 shows a screen capture of the
beam direction portion of MacNCTPlan.
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Figure 2.8 MacNCTPlan Screen Capture of Beam Positioning
The final important step is the creation of the head model, a 21 cm by 21 cm by
25 cm lattice of 1 cm3 cells. The CT data in each cell are represented as a certain
percentage of soft tissue, tumor, bone and air, rounded to the nearest twenty percent.
This averaging process uses nearby pixels in the same plane, as well as adjacent planes.
After voxelization, each cell's location and composition is saved to a materials file. This
file also includes the beam entrance and exit locations, thresholding values and
anticipated boron concentrations for each beam set in previous portions of MacNCTPlan.
Figure 2.9 shows a CT slice and its corresponding voxelized data.
Figure 2.9 MacNCTPlan CT Voxelization
2.2.3. MPREP
More information is needed to create an MCNP input deck. The FORTRAN 77
program MPREP incorporates the MacNCTPlan materials file with files containing other
information necessary for MCNP. The spatial, angular and energy characteristics of the
neutron and photon beams, as well as the kerma factors for each dose component are
required. MPREP also prepares this information in the format required for the MCNP
input deck, calculating the necessary surfaces, planes, and material fractions.
The MCNP materials themselves are each a different combination of air, bone,
tumor and soft tissue. For example, MCNP material 11 is 20 % bone, 80% normal tissue,
while MCNP material 32 is 20 % tumor, 40 % bone, 20 % normal tissue and 20% air.
This material may appear in a cell containing the scalp and some surrounding air, the
cranium and a portion of a tumor near the surface. There are fifty six combinations of
materials, although not all of them are used in a given model.
MPREP converts the cells into the appropriate lattice model. It can also represent
the cells individually, without the lattice structure. Since MCNP cannot have photon and
neutron sources in the same input deck, MPREP creates photon and neutron input decks
for each beam. Figure 2.10 shows the head model of the non lattice version. The
visualization program Sabrina cannot display lattices, although the picture would be
similar. The two versions, lattice and non lattice, have different memory requirements
and run times, as described in sections 2.3.1 and 2.3.2.
Figure 2.10 Sabrina 3-D representation of the head model. The head is pointing to the left.
2.2.4. MCNP Calculations
After the neutron and photon input decks are created for each beam, MCNP uses
them to calculate the dose rates for each voxel. A more detailed explanation of the input
decks is given in chapter 3. Typically, one to three million particle histories are used to
for scoping runs, which generate results with 5% statistical error in the region of interest.
A description of this error and the number of particles used in scoping runs is given in
section 3.1.1.
2.2.5. MacNCTPlan Part II
After MCNP calculates the dose rates, the second part of MacNCTPlan is entered.
The voxel dose rates for each beam are loaded into MacNCTPlan. From this information,
MacNCTPlan interpolates the dose rate to each pixel using a 3D cubic spline. The dose
rate data are then shown as isodose contours superimposed over the brain morphology.
Tumor and normal tissue isodose rate contours are separately displayed superimposed
over the entire brain. The medical physicist then compares the therapeutic ratio of the
minimum tumor dose rate to the maximum normal tissue dose rate, assuming some
average boron concentration for each.
The maximum and minimum ratio of tumor dose rate to maximum normal tissue
dose rate is then determined for various beam orientations. Using MacNCTPlan, various
slices of the tumor are viewed and the appropriate dose rate is recorded. MacNCTPlan
can calculate this ratio when the user specifies the normalization factor to be the healthy
tissue maximum dose rate, so isoratio contours are plotted. Both visualization techniques
allow the medical physicist to obtain an understanding of the volumes encircled by a
particular threshold. With the current MIT epithermal neutron beam, the maximum
therapeutic ratio is on the order of three or four. The minimum depends heavily on tumor
location, and can be less than one for deep tumors.
In cases where the tumor is located near the eyes or optic chiasm, the dose rate to
these radiation sensitive structures is determined. If a dual beam irradiation is being
considered, the dose distributions from both beams are assessed. To calculate the dose to
a sensitive structure, it is assumed that the maximum dose rate location will receive the
prescription dose. The prescription dose can then be divided by the ratio of the dose rates
to the sensitive structure and the maximum tissue location to determine the absolute dose
to these locations. If the dose is unacceptably high, another beam orientation or
weighting is selected. The dose to parotid glands, a sensitive structure as reported by
Brookhaven National Laboratory (BNL), is also occasionally evaluated if they are in high
dose rate locations. To lower the dose to these structures, a posterior beam entry was
used.
Although MacNCTPlan gives the medical physicist absolute control over where
to place the beams, the actual physical setup used will be limited by the range of the
subject positioning device (couch) and the subject's tolerance of discomfort and his or her
flexibility. Typical limitations are around twelve degrees lateral tilt of the positioning
device, combined with the subject's physical ability to turn his or her neck. For example,
irradiation beams cannot be directed into the center of the back of the head in a transverse
plane because the subject cannot be placed face down, nor would it be optimal for the
beam to pass throughout the positioning device's headrest.
Occasionally, the medical physicist determines that a small dose to the deep
portions of a tumor from a beam entering the contralateral side of the subject's head will
yield the best therapeutic ratio. This effect can be accounted for by adjusting a fluence
weighting factor. It is the ratio of neutron fluence in the second beam to that of the first.
Since the neutron fluence rates may vary slightly, this ratio is not strictly the ratio of the
length of irradiations, but is often considered as such.
The physician will occasionally be interested in the use of dose volume
histograms (DVH). These can be generated within MacNCTPlan or calculated in an
Excel spreadsheet directly from the MCNP data (see section 5.1). In MacNCTPlan Part
II, the tumor ROIs can be used as a guide to determine the volume of interest, or the brain
tissue or a sensitive structure volume can be outlined and defined as the new ROI.
MacNCTPlan will automatically calculate the volume identified, and the relative volume
containing a certain dose rate or higher. Below is a screen shot of MacNCTPlan's dose
rate volume histogram (DRVH) generation ability. Since the effects of different °B
concentrations and irradiation times can be included, these DRVHs will show an identical
shape as the DVH.
After the final beam selection has been made, each final beam calculation is run
for ten million source particles, which results in one or two percent error of total dose to
the tumor region. This calculation typically requires a run time of fourteen hours on a
200 MHz Pentium Pro computer.
2.3 Monte Carlo N Particle Radiation Transport Code (MCNP)
Determining dose rates to locations in the subject is an integral part of BNCT
treatment planning. The Monte Carlo radiation transport code, MCNP, is the integral part
of calculating the dose rates. MCNP, a well tested and documented code developed by
Los Alamos National Laboratory (LANL), is successful at simulating the complexities of
the irradiation. As mentioned before, it is capable of representing the subject's head, the
energy, angular, and radial distributions of the neutrons and gammas emitted from the
MITR-II Medical room's epithermal neutron beam. Since the beam contains thermal,
epithermal and fast neutron components, MCNP's detailed transport calculations are used
to calculate the thermalization and subsequent dose of neutrons through elastic and
inelastic collisions with varying isotopes, in addition to the photons created by neutron
absorption. When elevated concentrations of 'OB are present in the model, MCNP
calculates the amount of flux depression and the corresponding change in the dose
distribution. MCNP does not track the radiations from the delayed decay of
radioisotopes, nor does MCNP include photoneutron creation.
MCNP uses an input file, or input deck, that completely describes the model of
the problem that the user wants to simulate. Everything from source characteristics to
output format is controlled through this input deck. Significant components of a deck
used for BNCT treatment planing are the geometric patient model, either lattice or non
lattice based, materials entries, source description, kerma factors and tallies. Each of
these is described in detail in this chapter. For a more complete description of input deck
options, the reader should refer to the MCNP 4B Manual 2.
2.3.1 Lattice Model
The lattice model of MCNP is a geometric structure: a grid of regular hexahedra,
either cubes or triangular prisms. The grid is formed by an infinitely repeating array of
regularly spaced planes. A contiguous region of space bounded by these planes is a
single lattice element. Since each lattice element can contain several objects, including
other nested lattices, a system of layers, or universes, is used to fully describe the model.
A universe is a region of infinite space.
The universe structure for the BNCT patient modeling involves three levels, as
illustrated in two dimensions in Fig 2.11.
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Figure 2.11 Illustration of Multiple Universe Levels.
shown, each lattice element has a corresponding cell.
Although only one cell in universe level three is
The root universe, or "highest" level, contains the "window" (cell 1001) looking
onto the lattice level. Since the lattice is an infinitely repeating structure, it is this
"window" which defines how much of the lattice will be visible in the root level, or used
for transport. The window is filled with universe 100, which is a cubic lattice (cell 1000).
Each lattice element is filled with a lower level universe. This third and lowest level
contains cells (cells 1-56) with specified material properties. Just as in the lattice cell,
only the portion of these cells that corresponds to the movement of the particle through
the lattice element will actually be used. The other two cells in the root level, cell 1002
and 1003, define everywhere external to this window. Cell 1002 is the region of air
surrounding the 21 cm by 21 cm by 25 cm model where neutron and photon transport is
important. Cell 1003 is a sphere beyond which no transport occurs. Particles passing
into cell 1003 are terminated.
The portion of the Harvard/MIT BNCT treatment planning input deck describing
the above model is shown in figure 2.12.
c cell cards
c
1000 0 -112 111 -212 211 -312 311
lat=l fill= 0: 20 0: 20 0: 24
56 56 56 56 56 56 56 56 56 56 26 26 26 26 1 26 56 56 56 56 56 56
[many more lines of data]
56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56
u=100
1 1 -1.04700E+00 -70 u= 1
[all other universe material cards]
56 56 -1.29300E-03 -70 u= 56
1001 0 111 -113 211 -213 311 -313 fill=100 $ Window
1002 0 -1000 ( -111: 113: -211: 213: -311: 313) $ Outside Window
1003 0 1000 $ No Transport Beyond
Here
c BLANK LINE
c BLANK LINE
c
c surface cards
111 px -10.500000 $ Set of Planes in X direction
112 px -9.500000
113 px 10.500000
211 py -10.500000 $ Set of Planes in X direction
212 py -9.500000
213 py 10.500000
311 pz -10.500000 $ Set of Planes in X direction
312 pz -9.500000
313 pz 10.500000
1000 so 5.56417E+01
70 so 5.56417E+01
c
Figure 2.12 MCNP Lattice cells and surfaces.
In this example, cell 1000, the lattice, has material zero (i.e. void), and is bounded
by the planes 112, 111, etc. These planes form a single 1 cm 3 voxel. Although this voxel
is repeated infinitely in the three Cartesian directions, the window bounded by planes
111, 113, etc., limits transport in that universe level. The location of this voxel is such
that the center voxel of the entire 21 cm by 21 cm by 25 cm matrix of voxels is at the
coordinate (0, 0, 0). The order of the listed planes is important in defining the indices and
in what direction they increase. Since 112 is listed first, the voxel in the same y, z
location but at -9.0 would be [1,0,0]. The lat=l option specifies that the lattice is filled
with hexahedra, while lat=-2 would fill the lattice with hexagonal prisms. The fill option
specifies the number of the universe in the next lower level. The listing of fifty-six
different universes for each of the 11025 lattice elements specifies which universe each
lattice element is filled by. After the lattice cell entry is a listing of fifty-six cells, each
specifying a density and material, 1 through 56, belonging to their corresponding
universe listed on the lattice card. These cells, although they could be cubes or any other
shape that defines the bounding surfaces of a cell, are spheres for simplicity.
After the cell listings is a blank line followed by the surface listings. These
surface cards describe planes and spheres that bound the lattice and the regions of
importance. This input file uses the new ability of MCNP4B to have coincident window
and lattice bounding planes, previously a small offset was required Although not shown
above, the imp card sets the importance of every cell to 1, except cell 1003, the external
world, which is set to zero.
2.3.2 Non Lattice Model
The standard cell geometry of MCNP fully describes the location, material, and
boundaries of each of the 11025 cells, without using lattices or multiple universe levels.
Figure 2.13 shows a portion of the input deck where all planes and cells are listed
explicitly.
c cell cards
c
1 56 -0.12930E-02 11i
2 56 -0.12930E-02 112
3 56 -0.12930E-02 113
[many cell cards]
11025 56 -0.12930E-02 131
11026 0 -1000 ( -111:
11027 0 1000
c BLANK LINE
c BLANK LINE
c
111 px -10.500000
112 px -9.500000
113 px -8.500000
114 px -7.500000
115 px -6.500000
[many other px, py, pz planes]
Figure 2.13 MCNP non-lattice cells and surfaces.
-112
-113
-114
211 -212
211 -212
211 -212
311 -312
311 -312
311 -312
-132 231 -232 335 -336
132: -211: 232: -311: 336)
The non lattice neutron and gamma BNCT problems require forty-six and forty-
three Megabytes of RAM, respectively. These memory requirements are large enough to
prevent MCNP from operating within a Windows NT DOS window. The standard
MCNP4B lattice version decreases these memory requirements to nineteen and fourteen
Mbytes, but it prohibitively increases wall clock runtimes, by a factor of about one
hundred. The non lattice model capability is useful to retain for running on other
platforms, such as UNIX, especially when MCNP cannot be recompiled with time
reducing enhancements, and for model visualization with Sabrina. During the
Harvard/MIT treatment planning calculations, the lattice model is used exclusively.
2.3.3 MCNP Materials
MCNP requires a description of the matter that fills any location. The materials
card provides a description of the isotopes and abundances, as well as the cross section
library associated with each isotope. Figure 2.14 is a part of the materials portion of the
input deck.
ml 1001.50c -0.1058481 6012.50c -0.1395953 7014.50c
8016.50c -0.7269170 15031.50c -0.0039055 17000.50c
19000.50c -0.0039055 5010.50c -0.0000010
m2 1001.50c -0.1058481 6012.50c -0.1395953 7014.50c
8016.50c -0.7269168 15031.50c -0.0039055 17000.50c
19000.50c -0.0039055 5010.50c -0.0000012
m3 1001.50c -0.1058480 6012.50c -0.1395952 7014.50c
8016.50c -0.7269167 15031.50c -0.0039055 17000.50c
19000.50c -0.0039055 5010.50c -0.0000014
[portion removed]
m52 1001.50c -0.0499354 6012.50c -0.1398192 7014.50c
8016.50c -0.4497058 15031.50c -0.1098579 20000.50c
m53 1001.50c -0.1053278 6012.50c -0.1389091 7014.50c
8016.50c -0.7244360 15031.50c -0.0038863 17000.50c
19000.50c -0.0038863 5010.50c -0.0000010
m54 1001.50c -0.1053277 6012.50c -0.1389090 7014.50c
8016.50c -0.7244353 15031.50c -0.0038863 17000.50c
19000.50c -0.0038863 5010.50c -0.0000020
m55 1001.50c -0.0498282 6012.50c -0.1395189 7014.50c
8016.50c -0.4492173 15031.50c -0.1096220 20000.50c
m56 7014.50c -0.7778000 8016.50c -0.2222000
-0.0184258
-0.0014020
-0.0184258
-0.0014020
-0.0184258
-0.0014020
-0.0409527
-0.2097288
-0.0221585
-0.0013951
-0.0221585
-0.0013951
-0.0425352
-0.2092784
Figure 2.14 Materials Cards in MCNP BNCT treatment planning input deck.
The ml states that for material one, an isotope with atomic number of one and
atomic mass of 001, i.e. 'H, is present with a mass fraction of 0.1058481, an isotope with
an atomic number of 6 and atomic mass of 012, i.e. 12C, is present with a mass
abundance of 0.1395953, etc. The ".50c" after each isotope identification indicates that
the continuous cross sectional data from the Evaluated Nuclear Data File (ENDF) V
library data set, should be used. The minus sign indicates the mass fraction rather than
atomic fraction is used. Densities are specified in the cell cards.
As indicated in Chapter two, each of these materials corresponds to a different
fractional combination of air, tissue, bone and tumor or other ROI defined region of
space. Table 3.1 lists the combination of these in each material.
Table 3.1 MCNP Material Composition Fractions
AIR BONE NORMAL TISSUE TUMOR MCNP Material
0 0 0 100 1
0 0 20 80 2
0 0 40 60 3
0 0 60 40 4
0 0 80 20 5
0 0 100 0 6
0 20 0 80 7
0 20 20 60 8
0 20 40 40 9
0 20 60 20 10
0 20 80 0 11
0 40 0 60 12
0 40 20 40 13
0 40 40 20 14
0 40 60 0 15
0 60 0 40 16
0 60 20 20 17
0 60 40 0 18
0 80 0 20 19
0 80 20 0 20
0 100 0 0 21
20 0 0 80 22
20 0 20 60 23
20 0 40 40 24
20 0 60 20 25
20 0 80 0 26
20 20 0 60 27
20 20 20 40 28
20 20 40 20 29
20 20 60 0 30
20 40 0 40 31
20 40 20 20 32
20 40 40 0 33
20 60 0 20 34
20 60 20 0 35
20 80 0 0 36
40 0 0 60 37
40 0 20 40 38
40 0 40 20 39
40 0 60 0 40
40 20 0 40 41
40 20 20 20 42
40 20 40 0 43
40 40 0 20 44
40 40 20 0 45
40 60 0 0 46
60 0 0 40 47
60 0 20 20 48
60 0 40 0 49
60 20 0 20 50
60 20 20 0 51
60 40 0 0 52
80 0 0 20 53
80 0 20 0 54
80 20 0 0 55
100 0 0 0 56
Although there are fifty six materials listed, not all of them are significantly
different. The difference between materials three and four, one sixty percent tumor forty
percent tissue, and the other forty percent tumor sixty percent tissue, is extremely small.
A more significant difference is that only tissue and tumor cells explicitly contain boron,
5010.50c. The last material, fifty-six, is pure air containing only nitrogen and oxygen.
Associated with each of these materials, except air, is cross sections adjustment defined
by an S(ax,) data set for particles of energy below 4 eV. These adjustments represent
significant molecular influences on neutron scattering below 2 eV. These adjustments are
not available for tissue, but they are available for light water. Specifically, the cross
section correction for 'H in light water is applied, but no modification to 160 is
available' 2. The card used to apply the S(a,p) adjustments for material 1 is:
mtl lwtr. Olt
The . it specifies the temperature of the light water is 300 K. The available S(ca,p) data
are given in Appendix G.II. of the MCNP4B Manual.
2.3.4 Neutron and Photon Source
An accurate representation of the radiation source is essential for proper
simulation of an irradiation. The BNCT treatment planning neutron and photon input
decks each have detailed source descriptions, representing the irradiation beam as a disk
source with spatial, energy and angular distributions. The disk has a specific location and
orientation associated with it, which is defined by the medical physicist to have a specific
orientation with respect to the patient. While the patient is physically moved to a specific
orientation with respect to a fixed radiation beam in the BNCT irradiation, within
MCNP, the patient model is fixed and the source is moved.
Within the MCNP input deck, the particle source for the BNCT problems is
defined by the sdef card, the general source definition. The variables rad, pos,
axs, and ext specify the distribution and locations of source particles. The pos
modifier specifies the position of the disk's center, while the axs specifies the vector
normal to the disk's surface. Ext is used to determine the distance from the disk's
surface a particle is created. The default ext option is zero, indicating the source is a
disk source, rather than a cylinder. Rad specifies the radius of the disk. The vec and
dir variables specify the range and distribution of the source particle's directions. The
vec modifier specifies the direction the created particle is traveling. Dir specifies the
angle or distribution about the vec that particles will be created in. The cosine of this
angle is t. The above variables are illustrated in Figure. 2.15.
DIR VEC
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Figure 2.15 Particle Creation Modifiers for a Cylindrical Source. A particle's initial location, indicated by
the solid black dot, is described by the specified position (POS), axis (AXS) and radius (RAD). The
particle's initial direction is modified by a vector (VEC) and [t (DIR), the angle between the particle's
initial direction and the specified vector.
Each of the above variables can be specified by a single discrete value or
distribution of values, allowing the user to model complicated distributions in phase
space. To specify a distribution, the user sets the variable equal to some distribution, d#.
Accompanying si # and sp# cards specify if the distribution is predefined or entered by
the user. In several instances, it is useful to correlate distributions. Making one
distribution a function of a previously determined variable is done by setting the sdef
variable equal to fXXX, where XXX is the independent variable. For example,
eng=frad d2 sets the energy for a particular particle equal to a value or distribution
depending on what the radius of that particle was determined to be.
The MITR-II M67 epithermal beam is represented as a function of radial position,
energy and direction26 12. This model of the neutron and gamma component of the beam
is based on three radial bins. The angular and energy distributions, having 3 and 93 bins
respectively, are each functions of the radial bin, but are independent of each other. This
is conceptually illustrated in Fig 2.16.
A=1
Azimuthal Angle, 0
Outermost Innermost Middle Radial Bin
Radial Bin Radial Bin
Figure 2.16 Correlated radial and angular distributions in a hypothetical BNCT disk gamma source.
The above figure shows a hypothetical polar plot of the direction and energy distributions for a particle created in
the center of a given radial bin. The center bin is foreword peaked, the middle bin is nearly isotropic, and the outer
radial bin is greatly outward peaked. The shading of the radial bin is an indication of the relative number of
neutrons in that bin. Since the spatial sampling of neutrons within a radial bin was set to be constant in area, the
shading throughout a radial bin is constant. The shading of the radial bins indicates that energy distribution is
constant within a single radial bin, irrespective of the direction the particle is traveling. The patterns of color are
representative of the energy distribution in a bin. Higher energies are represented in red and yellow, while lower
energy photons are green and blue.
A significantly improved MCNP neutron source is currently being used27. It has
correlated energy and angular distributions in each radial bin, in addition to having increased detail
of distributions. This is done by spatially superimposing three radial groups, each with one of
three energy groups. Each of the nine distinct sources has its own angular distribution. The
radial, energy and angular distributions have sixteen, twenty and twenty six bins, respectively.
The effect is shown in Fig 2.17, which is different from 2.16 in its energy and radial distributions.
P=1
Azimuthal Angle, b
Outermost Innermost Middle Radial Bin
Radial Bin Radial Bin
Figure 2.17 Correlated angular, radial and energy distributions in a hypothetical neutron disk source.
The above figure shows a hypothetical neutron source with angular, radial and energy correlations. The length of
the black vectors represent the relative number of neutrons going in the vector's corresponding p direction. The
shading of the radial bins indicate that there is a distribution in the 16 radial bins. The patterns of color are
representative of the energy distribution in a bin. Higher energies are represented in red and yellow, while lower
energy photons are green and blue. The amount of a certain color a black vector passes through is proportional to
the probability its energy will be within that energy bin. Four energy bins are shown here.
As shown in Fig. 2.17, the innermost radial bin is greatly forward peaked, and the forward
peaked neutrons have a more energetic distribution within that bin, as indicated by the greater
proportion of red along the vector of a gt=1 source neutron. The middle radial bin is isotropic for
pt>0, as indicated by the constant length of the source particle direction vector in the polar plot.
The neutrons traveling perpendicular to the surface of the disk are also more energetic.
Conversely, the neutrons traveling more parallel to the surface of the disk, those with t- 1, have a
more thermal distribution. The neutrons created in the outer energy bin have a higher t
distribution and a more thermal distribution. Those few that are still traveling along t~-O have a
higher energy distribution.
2.3.5 Flux Tallies
MCNP can determine a number of quantities of interest. The surface averaged
current, surface averaged flux, cell averaged flux, flux at a point or ring detector, the
average energy deposited in a cell, or fission energy deposition can all be calculated by
using a tally card. These cards include information on what is to be calculated and what
cells or surfaces should be used. Since the dose rate averaged over a cell is the ultimate
goal for the BNCT treatment planning simulation, the F4: N (or F4: P) card, or cell
averaged flux card, is used to find the flux from neutrons and photons respectively. The
flux will be multiplied by the energy dependent KERMA to dose conversion factor.
When used with the lattice model, the card to calculate the cell averaged neutron flux in
every lattice element is:
f4:n (1000<1000[0:20 0:20 0:24])
The resulting value is the number of neutron per square centimeter per source neutron. In
order to find the dose rate, this value should be convolved with the energy dependent
energy deposited per neutron and multiplied by the total neutron current. The tally
multiplier card multiplies each cell averaged flux by the number specified. The card
shown below will multiply each of the 11025 lattice element "cell" fluxes by 5E 11 n/min,
which corresponds to the reactor power at 5 MW.
fm4 5.00000E+11
2.3.6 Flux to Dose Multipliers
MCNP uses the dose energy and dose function cards to convert neutron flux to
dose rate. These cards allow the user to enter energy dependent flux multipliers; the
Harvard/MIT BNCT treatment planning calculations use Kerma factors. The Kerma
factors are different for each dose component, either thermal or fast neutron, photon, or
boron. The kerma factors used in our treatment planning runs were calculated were from
the cross sections and nuclear reaction data 4. For convenience, these two cards are
entered in column format rather than in rows. The columns must be of equal length and
contain monotonically increasing energies. Figure 2.18 shows a portion of the DE DF
cards used to convert the photon fluence into photon dose rates.
# de34 df34
c Energy (Mev) Photon Brain Tissue
1.00e-03 5.45e-08
1.50e-03 3.00e-08
2.00e-03 1.83e-08
[many more entries]
1.45e+01 3.53e-09
1.50e+01 3.63e-09
Figure 2.18 Dose Cards in MCNP BNCT treatment planning input deck. For energies between listed
values, interpolation is log log.
Using the above methods of patient modeling, materials and source description
and appropriate tallies and dose conversions, MCNP calculates the dose to every voxel in
a simulated irradiation. MCNP is capable of handling the complexities of the irradiation
simulation, in addition to giving the knowledgeable user the flexibility to easily make
changes to the simulation.
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3. Treatment Planning MCNP Run Time Reductions
The preceding chapters describe the typical Harvard/MIT BNCT treatment
planning process. Although functional, it was a time consuming process, taking more
than three days for each subject. If BNCT is proven to be effective and integrated into
mainstream medical therapies, the procedure must be much more time efficient. Since
the Monte Carlo dose rate calculations accounted for two to three days of the process, it
was targeted for optimization. Three approaches for run time reduction were
investigated: use of an appropriate number of source particles, MCNP4B' source code
modifications and parallel computing. After verifying that the appropriate number of
source particles were being used with a voxel statistical error analysis described later, the
MCNP4B source code was modified by LANL personnel to decrease the runtime of a
lattice problem by a factor of nearly one hundred, although the resulting speedup was
only faster than the non lattice version by a factor of two. This enhanced version was
also modified to run in parallel, allowing factors of speedup roughly equal to the number
of computers used. The implementation and description of these three approaches are
described in sections 3.1, 3.2 and 3.3, while their verification is described in the last
section, 3.4.
Additional improvements were made to the BNCT dosimetry procedure, after the
discovery of a new phenomenon. When the time of the second beam of a two beam
irradiation was increased beyond the first irradiation duration, caused by unexpected
complications in the first beam irradiation, the maximum dose location moved. This
movement placed the maximum dose location in a much higher dose rate location,
leading to an underestimation of the delivered dose. To anticipate this effect in the
future, a table of dose rate contributions from various weighted beams can be generated
using existing capabilities within MacNCTPlan, which are currently used to find the dose
rate contributions for the anticipated treatment plan. This research is described in chapter
three of this thesis.
The final improvements from this thesis are the volume dosimetry calculations,
which include calculating the dose volume histograms and volume average doses for
tumor and normal tissue. The subject's dose volume histograms depend on the geometric
combination of the irradiation beams and dose cohort grouping. An analysis of the
subject volume doses leads to a proposed alternative cohort grouping.
3.1 Uncertainty Analysis
The first obvious means of reducing the runtime of the beam calculations is to
reduce the number of source particles. While this will increase the error associated with
the dose rates calculated, it may still be within acceptable bounds. For example, in
scoping runs, if only a rough distribution of dose in the target body part is needed, or if
only a high dose rate regions near the tumor are important, then the uncertainty in
unimportant regions could be allowed to grow large, requiring fewer particles and
decreasing run times. If the treatment employs parallel opposed beams, where a beam is
used to increase the dose rate to the deep side of the tumor by passing through the bulk of
the body part, a larger number of particles needs to be run to accurately evaluate the
effect of the second beam at that distal location. The effects of number of particle
histories on statistical uncertainty of the voxel dose rates and the isodose rate contours
were investigated.
3.1.1 Voxel Dose Uncertainty Analysis
Total dose rates are the sum of five dose components, fast and thermal neutron,
structural and induced gammas, and boron. Each of these is product of the Relative
Biological Effectiveness (RBE), scaling factors, the boron concentration for the boron
component, and the physical dose rates calculated by MCNP. The relative error for the
total dose rate for each voxel is determined, via propagation of error, from the relative
uncertainty provided by MCNP for each dose rate component. Based on the error
propagation formula, equation 3.1, and the equation for the total dose rate, equation 3.2,
the total statistical dose rate error is shown in equation 3.3.
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Equation 3.1.
Equation 3.2.
Equation 3.3.
The total dose rate error for a specific voxel, GTDR (i), is the absolute computed
uncertainty (1 ) for the total dose rate, in RBE cGy, to voxel i. The relative Monte Carlo
uncertainty calculations by MCNP for voxel i and component f is represented as ,f (i).
The dose rate is represented by Dr(i). The product, f Df, is the error, af, for each voxel.
The above equations neglect the uncertainty in the RBE, boron concentration, and
scaling factors, which is substantial, but is not well known. The relative total dose rate
error is the absolute dose rate error divided by the total dose rate, and is plotted as a
function of number of source particles and dose rate in Fig. 3.1.
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Figure 3.1. Total dose rate uncertainty for various number of histories
Figure 3.1 shows the total dose rate relative error associated with every non air containing
cell for runs of five hundred thousand, one, three and ten million particles. The high dose rate
cells have the lowest relative error, while the lower dose rate regions have larger errors. The
results of this graph show the reduction of total dose rate uncertainty as the number of particles
increases.
" ., .:,•.°: .increases .
On Fig. 3.1, the appropriate number of source particles for various treatment plans
can be determined qualitatively. For single beam irradiation scoping runs, where only
high dose rate cells will be contributing to the tumor dose, only the higher dose rate cells
will need to be determined to 5% error. Figure 3.1 shows the dose rates to a region
receiving 1-2 RBE cGy/min with an uncertainty of 5% or less occurs roughly between
500,000 and 1,000,000 histories. For dual beam irradiations, where 0.5 to 1 RBE
cGy/min would be contributed to the tumor from the second beam, between one and three
million particle should be used in the scoping runs to obtain less than 5% uncertainty.
Figure 3.1 also shows that for dose volume histograms, where the dose throughout the
entire volume of neural tissue should have little uncertainty, ten million histories should
be run.
An analysis of the statistical uncertainty and the number of particles used shows
an agreement with the one over square root of N statistical law. For the highest dose rate
cell, the uncertainty associated with five hundred thousand particles is nearly 5%. When
a factor of twenty more particles are run, the uncertainty should be reduced by a factor of
one over 4.47, in close agreement to the 1% uncertainty of the error.
3.1.2 Isodose Rate Contour Analysis
While figure 3.1 may give a clear understanding of the error associated with
certain dose regions, the actual pictures from the isodose rate contours in MacNCTPlan
provide a different perspective. While the images do not incorporate the total dose rate
error, they will show the fluctuations of the total dose rates with the number of particles.
Figures 3.2 a-e show the MacNCTPlan isodose rate contours for the same subject and
beam orientation, but with different number of histories.
Figure 3.2 a.
Subject 97-3 Two Hundred Fifty Thousand Particles
Figure 3.2 c.
Subject 97-3 One Million Particles
Figure 3.2 b
Subject 97-3 Five Hundred Thousand Particles
Figure 3.2 d
Subject 97-3 Three Million Particles
Figure 3.2 e.
Subject 97-3 Ten Million Particles
The above figures show the isodose rate contours from a single irradiation beam entering from the left.
The contours outline the following fractional dose rates from the peak dose rate: 95, 90, 80, 70, 60, 50, 40,
30, 20, 15, 10, 5.
The above images, all of the same cross section of the same subject, illustrate
several points. The high dose rate region gradually increases by ten percent in dose and
physical size as the number of particles increases. All contours become less erratic and
more representative of a continuous dose distribution as the number of particles increases.
The two lowest trials (Fig 3.2 a,b) also have the bottom edge of the tumor in an isodose
rate region five percent lower than the final ten million history run (Fig 3.2e).
A quick comparison between the error estimates and the isodose rate contours
show that the error restrictions are the more restrictive of the two. If the number of
histories needed to be run was based on the isodose rate contours only, the number of
histories would be too few by almost a factor of two. As seen in fig 3.2e, the tumor
receives forty-five percent of the maximum dose at its lowest point, or roughly 2.7 RBE
cGy/min. On Fig 3.1, which is derived from the same subject MCNP data, the error
associated with the one million history runs, for voxels receiving a dose rate of 2.7 RBE
cGy/min or higher, is within five percent. From figures 3.1 a-e, the tip of the tumor would
be within five percent of its final value somewhere between one million and five hundred
thousand. The scoping run for this subject was one million particles.
For the ten million history final run, the errors are much less. The statistical error
is within two percent in the regions of interest and within three percent for almost all
voxels. The isodose curves are smooth and well defined.
Since the number of particles cannot be reduced further without unacceptable
increases in statistical uncertainty, additional methods of reducing the run times were
investigated.
3.2 MCNP Source Code Improvements
Several modifications were made to the source code by Los Alamos National
Laboratory to increase the quality and speed of MCNP. MCNP4B was released February
1997, adding several improvements over MCNP4A 2. While no changes were made to the
neutron and gamma transport physics, the electron physics was improved. Other
improvements allow greater flexibility, such as differential operator perturbations and
improved cross section plotting features. While the unmodified MCNP4B does run
slightly slower than MCNP4A, source code enhancements by Los Alamos National
Laboratory personnel removed unnecessary features and tailored the MCNP4B
executable for Harvard/MIT BNCT treatment planning calculations, greatly increasing
the executable's speed. As part of this thesis, these changes were verified and
implemented in the HARVARD/MIT Treatment Planning procedure. Utilization of
recently released FORTRAN compilers with better optimizing features also decreased
executable runtimes.
3.2.1 Tracking and Tally Patch
The MCNP source code can be greatly optimized for certain lattice problems.
Tracking and tallying optimizations were developed for the Harvard/MIT BNCT
treatment planning problem by Dr. Gregg McKinney and Dr. Ken Adams of LANL. The
tally optimization removes extraneous energy bins and tally modifiers, while retaining the
necessary tally multipliers and DE, DF cards that are used to convert volume averaged
neutron fluxes to dose rates. Tracking was made more efficient by removing checks for
generalized geometries and specifying that the voxels are enclosed by hexahedra. These
tracking and tally enhancements can be applied to the MCNP4B source code with a patch
file and the standard compilation procedure to create a specialized MCNP executable
called MCNPBNCT. These optimizations reduce the runtimes by factors of two for the
tracking modifications and fifty for the tallying modifications over the standard MCNP4B
code3 . This reduces the execution times of the lattice model below that of the standard
cell model, as shown in table 3.2 Furthermore, MCNPBNCT is compatible with the
Parallel Virtual Machine (PVM) multiprocessing code, allowing for further reductions in
runtimes.
Table 3.2 MCNP Wall Clock Run Times (min : sec)
NPS=10,000 NPS=1
M
Neutron Gamma Neutron Gamma
Lattice (NT) 503:56 71 51,000* 6,885*
Lattice w/ Enhancements (NT) 3:44 2:10 54:00 5:18
Lattice (Linux) 848:05 8:43 85,000* 341*
Lattice w/ Enhancements (Linux) 4:23 3:14 81:35 5:53
No Lattice (Linux) 19:18 5:50 199:53 51:03
The astrix denotes an estimated time, in minutes, the other values are measurements. Since the non-lattice
input deck would not run under NT, it was run under Linux.
3.2.2 Lahey FORTRAN 90
MCNPBNCT was compiled using the Windows version of the Lahey FORTRAN
90 compiler, LF90. It uses more efficient optimizations to create an executable ten to
fifteen percent faster than the previously used compiler, Lahey FORTRAN 77. The
primary disadvantage is the slow response to user interrupts (i.e., control-c) of the LF90
compiler, requiring the user to wait five to ten minutes before he or she can quit MCNP,
rather than after a few seconds with the F77 compiler.
3.2.3 GNU G77
An alternate compiler investigated was the GNU G77 compiler. The GNU suite
of tools, including FORTRAN and C compilers, as well as networking and system tools,
works under a variety of platforms, including Linux, UNIX and Windows. The GNU
compiler was used to compile MCNP on a PC running Linux. The resulting executable
was roughly ten percent slower than the LF90 on Windows. Since the operating systems
also changed, the runtime reduction attributed to the compilers themselves should not be
compared, only the final runtimes of the executables they create.
The combination of compiling with the Lahey F90 compiler and source code
enhancements reduced the wall clock runtimes to thirty percent of the previously used
executable. Although this advantage was significant, more dramatic improvements were
made by running MCNP in parallel.
3.3. Parallel Calculations
A principal method of MCNP speedup involves the utilization of additional
CPU's. While the ability to run MCNP in parallel existed in MCNP4A, it was primarily
implemented on architectures other than PC's (i.e. UNIX, SGI). MCNP utilizes the
computer program PVM, developed by Oak Ridge National Laboratories, to spawn
subtasks and pass messages between a linked network of heterogeneous computers4'5' 6.
Since each source particle history is independent of the previous history, with the
exception of the beginning random number used, Monte Carlo transport problems are
readily adapted for running simultaneously over multiple CPUs.
Since the Harvard/MIT team previously ran MCNP treatment planning jobs
individually on two Pentium Pro 200 MHz computers, the parallel capability of these
computers was investigated. Previous efforts to link IBM personal computers such as
these and run MCNP have centered on Linux. Cameron Kellough tested MCNP4A in
parallel on PC's running Linux in the summer of 1996', but no one had tested MCNP4B
in parallel on PC's. In addition to the new version of MCNP that had been released since
his work, the Linux kernel, GNU C compiler, and GNU FORTRAN compiler had all
undergone upgrades. The successful installation of the parallel version of MCNP is
detailed in section 3.3.3. Installation attempts on other operating systems, including
Windows, Linux-pmac and MkLinux are described in the Appendix A.
3.3.1 Linux Installation
Linux installation and testing was performed on several computers both at Los
Alamos and MIT. Each institution had two Micron Pentium Pro computers with 200
MHz processors and a single Sager 166 MHz Pentium laptop. Linux installation was
successful with both Red Hat and Slakware Linux distributions. Both include the
necessary networking tools needed for PVM. After installation, the Linux kernel was
rebuilt for each machine to account for differences in the network cards. After Linux was
installed, MCNP4B was installed and tested, as well as the required cross section
libraries. The final MCNP4B Linux executable was able to pass all of the test problems
except one. The verification of MCNP4B and MCNPBNCT is discussed in section 3.4.
3.3.2 PVM Installation
The several recent releases of PVM can be obtained via anonymous ftp to
netlib2.cs.utk.edu. PVM was then installed on each machine, by decompressing the
downloaded file and typing "make pvm." The environmental variables PVM_ROOT and
PVMARCH were set, and the PVM directory, pvm3/bin/Linux was created in the users
home directory. Appropriate remote permissions were set by adding the user's name to
the .hosts file in his home directory. After starting PVM by typing "pvm" and adding
remote machines with the "add" command, pvm was tested. The PVM test problems,
such as "hello" and "hello_other", which test remote execution of programs on other
linked computers, were used to verify the functionality of PVM.
3.3.3 MCNP Parallel version
MCNP4B was remade with PVM options and linked to the PVM libraries,
creating a parallel version of MCNP, "mcnp.pvm"'. This version was tested with a test
set of problems designed for multitasking. The final Linux pvm enabled MCNP4B
executable performed well, only failing two checks out of twenty nine. To further verify
its results, a BNCT treatment planning run was compared with results from the original
version. All verification efforts are described in section 3.4.
3.3.4 Speedup Results
Running MCNPBNCT on the Linux operating system on two Micron 200 MHz
Pentium Pro computers, the decrease in wall clock times over the previous version,
MCNPNEDH, is significant. Table 3.3 shows the improvement for various numbers of
histories run.
Table 3.3 Wall clock run times, in minutes, for a single beam evaluation
Number of Particles Tracked MCNPNEDH MCNPBNCT w/ PVM
250,000 45 (0.8 hrs) 23 (0.4 hrs)
500,000 87 (1.5 hrs) 34 (0.5 hrs)
1,000,000 150 (2.5 hrs) 59 (1.0 hrs)
3,000,000 507 (8.5 hrs) 172 (2.8 hrs)
10,000,000 1441 (24 hrs) 534 (8.9 hrs)
The number of particles refers to both the number of source photons and neutrons. The times given are
actually the sum of these two separate runs.
The combination of the tracking and tallying enhancements and PVM
significantly reduced wall clock runtimes. The single beam scoping evaluation of both
the neutron and gamma components, previously totaling one hundred fifty minutes on
one 200 MHz Pentium Pro running MCNPNEDH, was reduced to fifty nine minutes
using two 200 MHz Pentium Pros. The runtimes for MCNPNEDH, MCNPBNCT with
the lattice and non lattice geometry, and the PVM enabled MCNPBNCT lattice model
with two 200 MHz Pentium Pro's are shown in Figure 3.2
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Figure 3.3. Total wall clock runtimes for a single beam evaluation. The uncertainty associated
with each point is less than three minutes, i.e. background operating system processes will negligibly affect
the runtimes. The numbers in parentheses in the key are how many CPUs were added to the virtual
machine.
Since the speed gain associated with running in parallel is a factor roughly that of
the number of computers used" '0, the time for a single task could be reduced
significantly. The estimated effects of adding two and eight additional 200 MHz
Pentium Pro computers of equal power to the virtual machine are shown in Table 3.4
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Table 3.4 MCNP Speedup Summary - Total Wall Clock Runtimes
Source Particles MCNPNEDH MCNPBNCT MCNPBNCT MCNPBNCT MCNPBNCT
Tracked 1 CPU 2 CPU's 4 CPU's* 10 CPU's 10 CPU's
min (hrs) min (hrs) min (hrs) min (hrs) min (hrs)
250,000 45 (0.8) 23 (0.4) 15 (0.2) 9 (0.2)* 2 (0.03)**
500,000 87 (1.5) 34 (0.5) 20 (0.3) 12 (0.2)* 3 (0.05)**
1,000,000 150 (2.5) 59 (1.0) 33 (0.5) 17 (0.3)* 4 (0.07)**
3,000,000 507 (8.5) 172 (2.8) 89(1.5) 39 (0.7)* 9 (0.15)**
10,000,000 1441 (24) 534 (8.9) 270 (4.5) 112 (1.9)* 25 (0.4)**
A *,** indicates that the times are estimates, not measurements. *Estimates are based on proportional
decrease in MCNP ctm time, while startup times remain the same. **Estimates are also based on
proportional decreases in total computing time, due to increase in processor speed.
These projected times show that efficient treatment planning beam evaluations can be
achieved, minimizing scheduling conflicts and possibly allowing real time treatment
planning. An anticipated future project will allow MCNPBNCT to be run in parallel over
ten 900 MHz CPUs. This will lower the calculation time to minutes, as shown in the last
column of table 3.2.
3.3.3 Running MCNP in Parallel
After PVM was installed on both Linux computers, the parallel version of
MCNPBNCT was tested and verified. Afterward, the combinations of multitasking
parameters and computational power were studied. Total runtimes were evaluated using
a heterogeneous computing network. Even though a single treatment planning beam
evaluation will be completed in the least amount of time by using PVM, the BNCT
treatment planning process requires the optimization of several beams, which is most
efficiently done by running each beam without PVM, when the number of beam
evaluations exceeds the number of available computers.
The parallel version of MCNP4B has the ability to perform load balancing'. The
master MCNP executable, which is the one started by the user, identifies the number of
subtasks to be started from the command line option "tasks #". The number entered can
be larger than, smaller than, or equal to the number of computers in the virtual machine.
The master task starts the subtasks sequentially using the PVM listing of potential hosts
in the virtual machine. If a negative number for the tasks option is entered, an equal
number of particles is run on all computers. A positive number will cause the master to
evaluate the computing power of all hosts with a limited number of particles. Both
options cause the slave subtasks to rendezvous with the master and relay to it the
appropriate information. If any of the subtasks have shutdown, the master identifies the
discrepancy and runs those particles. The frequency of rendezvous is controlled by the
fifth option on the MCNP PRDMP (print dump) card. The PVM load balancing requires
computational overhead, which is not needed on a homogeneous computing network.
The MCNP command line option "tasks -2" prevents this PVM optimization"18, and
hence is the best method for running in parallel on the Harvard/MIT BNCT homogeneous
network.
3.3.4 Job Identification and Importance
Analysis of the run time reduction due to PVM shows that although the use of
PVM does allow a single run to be completed much faster, it is not always an efficient
method of running multiple jobs. A pictoral representation is shown in Fig. 7.1 a-d.
Since there is some computational overhead from running PVM, using it will add to the
total computing power needed for the job. Speedup derives from the division of this total
computing power among all CPUs in the virtual machine. This results in a wall clock
runtime that is faster than the time for one job to be run on one computer. Figure 3.4
shows the PVM overhead and the reduction in wall clock times. If, however, several jobs
need to be run, and the number of jobs equals or exceeds the number of linked computers,
then each job should be run on only one computer to eliminate the overhead associated
with PVM, as illustrated in Figs 3.4c and 3.4d.
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Figure 3.4(a-d). Representation of Jobs and Optimization. Fig. 3.3a represents a single job being run
on one computer. Fig. 3.3b represents that same job being run on two computers with PVM. The
second smaller dark box on top is the computational overhead associated with PVM. Fig. 7.1c
represents two identical jobs being run on two computers without PVM. No additional overhead
occurs, nor is the wall clock time greater than in Fig. 7.1a. Fig. 7.1d show two jobs being run with
PVM on two computers. The total wall clock time is greater than in 7.1c. due to the PVM
computational overhead. The above figures exaggerate the PVM computational overhead, for
illustration.
For the BNCT treatment planning scoping evaluations, two single one million
source particle tasks (Fig. 3.4c) can be completed in one hour ten minutes, while two
sequential jobs, each run in parallel (Fig 3.4d) would be completed in one hour fifty nine
minutes. This difference is especially large since the parallel version would be run under
the slightly slower Linux operating system, effectively increasing the computational
overhead. For a final single beam, however, it is faster to run one job in parallel over the
two Pentium pros, as in Fig. 3.4b. The addition of five computers would make running
in parallel slightly more efficient for scoping runs, where each job would be distributed
over two computers, and significantly more efficient for the final run, where one or two
jobs could each be distributed among three or four computers.
3.4 Validations of calculation enhancements
The implementation of the new source code, MCNPBNCT, requires verification
before it can be used in treatment planning. Verification consists of two distinct
procedures, quality assurance on the code executable and a comparison of the code results
to MCNPNEDH.
3.4.1 MCNP4B Test Suite
LANL has several methods for testing and verifying the MCNP source code 1 '12
Included in these is the extensive testing of the source code through the use of twenty-
nine test problems. These test problems are run by the newly created executable and
compared with expected results. The scripts runprob and runprobmt verify the standard
and PVM versions of the executable. Both of these scripts should reference the DOS
MCTL and OUTP files, which need to be uncompressed on a DOS machine and
transferred via ASCII FTP to the Linux system. These scripts will compare the tally
output of the test problems to the reference tally output, the MCTAL files, using the
command "diff," which performs a line by line file comparison.
Unfortunately, the test suite utilizes portions of the code that were removed to
create MCNPBNCT, so it will not run the enhanced source code. Since MCNP4B had
not been verified on Linux, its validation was still important. When MCNP4B is run
without PVM, only one non-zero difference file, difml2, is created for the twelfth test
problem. It indicated that a different number of random numbers was used during this
execution than was used in the reference execution. This inconsistency may be attributed
to differences in the Lahey F77 and GNU F77 compilers. When run using PVM, four
non zero difm files will be created. Two of them, inpl2m and inp08am, do not track.
The other two, inp21am and inp28m, result from output differences caused by PVM's
rendezvous procedure, which is acceptable. Table 3.5 summarizing the difference files,
difml2, difm2la, and difm28, and the files themselves. Difm08a, beyond the header, is
too extensive to include here.
Table 3.5 Non-Zero Difm Files from MCNP4B on Linux.
-00 Optimization w/o PVM (runprob) w/ PVM (runprobmt)
File Size (bytes) Error Size (bytes) Error
difm08a N/A N/A 2669 tracking
difml2 128 tracking 3508 tracking
difm2la N/A N/A 1276 rendezvous
difm28 0 none 698 rendezvous
The above files were created when MCNP was compiled with -00 optimization.
Difm08a header - 2669 bytes
Icl
Difml2 - 146 bytes
1cl1
1579
1570
3000
3000
Difm21a - 1276 bytes
273c273,274
< tfc 10 1
20
1000
3000
5000
7000
9000
11000
13000
15000
17000
19000
309
10
1 1
4.09176E-05
4.08754E-05
4.55530E-05
4.26109E-05
4.09342E-05
4.71283E-05
4.66970E-05
4.50165E-05
5.70298E-05
5.48663E-05
1 1
:0 1 1
1000 4.09176E-05
1 22
22
3.71303E-01
1.78175E-01
1.68729E-01
1.35474E-01
1.15212E-01
1.23183E-01
1.11987E-01
1.04542E-01
2.23201E-01
2.07877E-01
1
1
3.71303E-01
21050
19337
4774870
4774894
1 23
1 23> tfc
1
274a276
275a278
276a280
277a282
278a284
279a286
280a288
281a290
282a292
298c308,
< tfc
1
> tfc
1
299a311
> 3000 4.08754E-05
300a313
> 5000 4.55530E-05
301a315
> 7000 4.26109E-05
302a317
> 9000 4.09342E-05
303a319
> 11000 4.71283E-05
304a321
> 13000 4.66970E-05
305a323
> 15000 4.50165E-05
306a325
> 17000 5.70298E-05
307a327
> 19000 5.48663E-05
Difm28 - 689 bytes
475,476c475,477
< tfc 9 1 1
1
< 3000 4.92945E-05
> tfc 13 1 1
1
> 2000 6.53503E-05
> 4000 5.91882E-05
478c479,480
< 9000 6.80561E-05
> 8000 7.29853E-05
> 10000 6.23468E-05
480c482,483
< 15000 5.00067E-05
> 14000 5.30353E-05
> 16000 6.61325E-05
482c485,486
< 21000 6.19494E-05
> 20000 5.87871E-05
> 22000 5.99188E-05
1.78175E-01
1.68729E-01
1.35474E-01
1.15212E-01
1.23183E-01
1.11987E-01
1.04542E-01
2.23201E-01
2.07877E-01
42
6.68206E-01
42
7.50077E-01
4.71549E-01
3.98976E-01
4.17453E-01
3.92323E-01
3.34972E-01
3.38257E-01
3.71568E-01
3.09465E-01
3.36357E-01
3.05517E-01
The above differences were created with a compilation of MCNP without
optimization. Although zero optimization produces the fewest number of difm files,
runtimes can often be considerably reduced at higher optimizations. When the -02
optimization is enabled, several difm files are created when runprob and runprobmt are
run, as listed in table 3.6.
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Table 3.6 Non-Zero Difm Files from MCNP4B -o2 on Linux
-02 Optimization w/o PVM (runprob) w/ PVM (runprobmt)
File Size (bytes) Error Size (bytes) Error
difm08a N/A N/A 2669 tracking
difm 12 3508 tracking 3508 tracking
difm2la N/A N/A 1276 rendezvous
difm28 0 none 698 rendezvous
difm29 1686 tracking 1686 tracking
difm29a N/A N/A 1686 tracking
The above files were created when MCNP was compiled with -02 optimization.
There are also CPU specific optimizations. The -m4 8 6 option is optimization for
the 486. The optimization for the Pentium is: -02 -m486 -malign-loops=2 -
malign-jumps=2 -malign-functions=2. There currently is no specific
optimization for the Pentium Pro. The differences between the 486 options and the
Pentium options on a Pentium Pro machine are negligible. Since optimizations above -
00 cause more problems not to track, they clearly change answers and thus are officially
unacceptable to LANL. Essentially the different number of random numbers being used
indicates that either a compiler or hardware error exists that may affect results for
particular features or subroutines within the MCNP source code. Since the treatment
planning jobs may not use the erroneous routines, it was compared with the previous
executable used.
3.4.2 MCNPNEDH MCNPBNCT Dose Rate Comparison
To verify the new code on Linux, a treatment planning calculation for one of the
previously subjects enrolled in the Harvard/MIT BNCT study was run using
MCNPBNCT in parallel and compared to the previous version, MCNPNEDH. This final
beam run used ten million source neutrons and ten million source photons, creating a well
converged result with small Monte Carlo uncertainties. Figure 3.4 compares the dose
rates in all non-air cells calculated by MCNPBNCT and MCNPNEDH.
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Figure 3.5 MCNP Dose Rate Comparison. Each point represents the difference for a single voxel.
Figure 3.5 shows the percent difference* in results between the previously used MCNP
version, MCNPNEDH and the final enhanced pvm version, MCNPBNCT, decrease as
dose increases. Even the lowest dose rate cells differ by no more than 5%. This shows
*% Difference(i) is 200*[MCNPNEDH DR(i)-MCNPBNCT DR(i)]/[MCNPNEHD DR(i)+MCNPBNCT
DR(i)], where DR(i) is the dose rate for the ith voxel.
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that the new version of MCNP is acceptable and can be relied on to reproduce the results
of the previous version.
Another way of looking at the data is to compare the difference between values
calculated by each of the two versions for the same voxel and their error bars. Figure 3.6
shows these data, in addition to a line that indicates that the error bars of a single voxel
are the same size as the difference between the two values for the same voxel.
0.04
0.02
0.00
-0.02
-0.04
0.00 0.01 0.02 0.03 0.04 0.05
MCNPBNCT Voxel Dose Rate Relative Error
Figure. 3.6 Comparison of Error for each non-air voxel. Each point represents a single voxel dose rate
comparison.
If most of the points were inside these lines, this would indicate the values were
converging. Since they are, this further validates that the two programs would yield the
similar dose rates for identical patient models and particle sources.
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4. Investigation of Peak Dose Location Movement During
Subject Irradiation and Dosimetry Effects.
The BNCT treatment planning procedure of the HARVARD/ MIT team relies on
calculated dose rates to evaluate various epithermal neutron irradiation beam orientations.
Often, one or more additional beams is used to increase the therapeutic ratio in deep parts
of the tumor. These additional beams can be of equal or fractional effective time with the
first beam, as indicated by its "weighting factor"'. Weighting factors, although strictly
the ratio of any beam's neutron fluence to the first beam's fluence, can be thought of as
the ratio of irradiation times, since the fluence rates are roughly constant with time.
MacNCTPlan can then combine the dose rate distributions by multiplying a voxel's
second beam dose rate by the second beams weighting factor and adding it to the first
beam's dose rate to the same voxel. The best therapeutic ratio can be determined by
changing the weighting factors of different combinations of beam orientations.
Using the final weighting factors and combination of all beams prescribed, the
global maximum dose rate can then be determined in MacNCTPlan. The prescription
dose could then divided by this dose rate to determine the neutron fluence, or effective
irradiation time, delivered from beam one, although it is actually determined using
phantom measurements, as described in chapter 2. Equation 4.1 states that the sum of the
dose rates for the combined global maximum dose rate location, CGM, times their
respective effective beam times is the prescription dose, D,.
D, = DRM tEff + DRCGM Eff Equation 4.1
P X BI B2 XB 2
Since the beam weighting factor for beam i, wi, is the ratio of tBi / tB1, it can be
substituted into Equation 4.1 for tBi, yielding equation 4.2.
DP t Eff Equation 4.2
(DR M+DRB W2 + ....)B - - ICGM
After the first beam's irradiation time is known, the others can be solved for using the
weighting factors.
4.1 Identification
Occasionally it is necessary to end the first beam irradiation prior to the
anticipated irradiation time due to subject discomfort or gradual misalignment with the
irradiation beam. The second beam irradiation time is then increased to achieve the
prescription dose. This changes the effective irradiation times, their ratios and the
realized weighting factors. If the changes do not disrupt the location of the global
maximum, the prescription dose can be achieved by increasing the second beam
irradiation and adding the additional dose to the integrated global maximum dose. For
combinations of low weighing factors, minimum beam shortening and certain beam
orientations, this process would yield the correct dose.
If the duration of the second beam is increased near to that of the first beam, the
location of the combined global maximum will move closer to the second beam's
maximum dose rate location. When this shift takes place, the combined global
maximum's dose rate will suddenly and dramatically increase, according to the beam's
relative position. For parallel opposed beams, this would cause an order of magnitude
increase in the dose rate as the CGM dose rate became the second beam's maximum dose
rate. Failure to take this change into account by continuing to use the second beam's
dose rate contribution to the global maximum will lead to a dose underestimation at EOI
that rapidly increases as time increases. Fortunately, it is possible to predict when this
change will take place and, in some cases, determine the new dose rates to the global
maximum.
4.2 Explanation
As mentioned in chapter 2, there is a distinct change in the dosimetry perspective
from dose rates to integral dose. In the treatment planning evaluation, dose rates from
different beams are combined using weighting factors. In effect, the beam irradiations are
applied simultaneously. During the actual irradiation, however, the beams are applied
sequentially. Dose rates vary significantly chronologically and spatially during the
multiple beam irradiation.
During the first dose fraction, the isodose distribution is straightforward. The
maximum dose rate occurs at the location determined solely that beam. Accordingly, the
maximum dose is located at the maximum dose rate location (MDRL). The global
maximum dose at the end of the first beam irradiation is the maximum dose rate
multiplied by the effective time. After a brief delay for subject repositioning, the second
fraction is delivered.
The second beam's dose distribution is a function of both the first and second
beams, although the maximum dose rate (MDR) is now solely determined by the second
beam. When the second beam is shorter than the first, the global maximum will remain
in the vicinity of the first beam's MDRL. The second beam is contributing a small
amount to the global maximum, the first beam's contribution to that point is significantly
higher. When the second beam is roughly equal to the first, the global maximum will
move in a manner related to the positioning of the two beams.
For roughly opposed beams, the global maximum will move to the opposite side
of the head quickly. During this short transition time, it is possible for the global
maximum to be at neither beam's maximum dose rate location. As the second beam's
effective irradiation time becomes much longer than the first, the global maximum will
move to the second beam's MDRL. The above process of global maximum movement
during a nearly parallel opposed beam irradiation is shown in figure 4.1, which is the
chronological dose reconstruction of one of the Harvard/MIT BNCT subjects, 96-4.
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Figure 4.1 Subject 96-4 Chronological Dose Reconstruction. The solid line shows the dose to the first
beam's maximum dose rate location. The dashed line shows the dose to the second beam's maximum dose
rate location on the other side of the subject's head. The dots represent the highest cumulative dose, the
global maximum, to any location within the subject's head.
Several important points are represented in figure 4.1. There are two plateaus in
the graph indicating times the beam was turned off. Since there was no neutron or
gamma fluence delivered, no dose was accumulated. The first plateau represents planned
subject repositioning; the second was an unexpected interruption in the irradiation beam.
Since the subject's head was reoriented to a nearly parallel opposed position with respect
to the irradiation beam, the dose rates change significantly after the first repositioning.
The movement of the global maximum is apparent near the end of irradiation. The
duration of the transition time is not obvious in the above graph, but shown in the blow
up of the region of interest, figure 4.2.
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Figure 4.2. Enlargement of Figure 4.1. Near EOI. Fig 4.2 shows the enlarged region of fig 4.1 near the end
of irradiation. Note the small time steps. The global maximum determined at 405.5, 405.7 and 405.9
minutes after the beginning of irradiation is not at either beam's maximum dose rate location.
In less than two minutes, the global maximum went through its transition period.
After this time, the global maximum dose rate greatly increased from 0.40 RBE cGy/min
to 5.57 RBE cGy/min. At the end of irradiation, the dose to the first beam's MDRL was
880 cGy, while the dose rate to the seconds beam's MDRL was 910 cGy. Five minutes
after the transition period began, the irradiation was concluded. Since this movement was
not anticipated, the online dosimetry used the same contribution of the second beam to
the global maximum, plotted along the solid line in Fig 4.2. This incorrect assumption
resulted in an overdose of 30 cGy, or 3.2 % of the final dose. Had the irradiation
continued, the dose underestimation and resulting overdose would have become
increasingly larger at a rate of 5.17 RBE cGy/min. Fortunately it is possible to calculate
when this effect occurs, providing a time frame that the second beam should conclude, or
dosimetry should be altered to account for the change.
For perpendicular beam orientations, the global maximum moves slowly. The
global maximum's location is much more sensitive to small changes in the duration of the
second beam's irradiation time. The chronological dose reconstruction for subject 97-3 is
shown below in Figure 4.3. and the expansion of the region of importance, in Figure 4.4.
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Figure 4.3 Subject 97-3 Chronological Dose Reconstruction. The solid line shows the dose to the first
beam's maximum dose rate location. The dashed line shows the dose to the second beam's maximum dose
rate location. The dots represent the highest cumulative dose to any location within the subject's head.
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Figure 4.4 Enlargement of Figure 4.3 near EOI. Subj. 97-4 Chronological Dose Reconstruction.
Figures 4.3 and 4.4 indicate several important differences to the previous parallel
opposed case. The first is the extended transition time, more than one hour in length, that
the global maximum was not in either beam's maximum dose rate location. Had the
irradiation continued, the transition time would have been much longer. Since the
transition time is significant, the global maximum is much larger, on the order of fifty to
seventy-five cGy, or five to eight percent, higher than the calculated dose at that time.
The difference between the parallel opposed and perpendicular beam irradiations
and their respective global maximum movements is the three dimensional combination of
their dose distributions. While the parallel opposed beams are essentially adding their
chronological dose vs. depth profiles, the spatial and temporal dose distributions include
the beam profile and scattering to a much higher degree. Thus it is possible for the dose
distribution, which peaks at one or two cm from a single beam, to peak at deeper depths
when multiple beams are applied in conjunction.
4.3 Prediction
Although it is difficult to predict when the transition begins or ends without full
knowledge of the dose rates to all locations, it is possible to calculate a rough estimation
easily for the parallel opposed cases, since the global maximum is almost always at one
of the two beam's MDRL. For a two beam irradiation, only four doses are needed: each
beam's dose rate contribution to each beam's maximum dose rate location. When the
accumulated doses at both MDRL's are equal, the global maximum is either in transition,
or simultaneously present in both locations. This "crossing over" condition, illustrated at
406.2 minutes after the beginning of irradiation in figure 4.2, is expressed mathematically
by:
BI * B  BI B 21B
2
DRB MDRL TB+ DRBI MDRL TB2 = DRBMDRL + DR2 MDRL T Equation 4.3
Where DR is dose rate and T is time. The subscript indicates location, the superscript
indicates fraction.
The duration of the second irradiation, TB2, is the only unknown. Solving for it produces
the following equation:
(DR BI BI TBI
DRI MDRL - DRB MDRL)I TB B( 2 = TB2  Equation 4.4
DDRB2MRL - DR MDRL
Due to various contributions from the unequal boron concentrations in the second beam
and geometric effects, the above factor will not be exactly one, but it should be close to it.
Exact determination of the global maximum movement time would require the
appropriate boron concentrations, which are not known until after the irradiation is
concluded. Fortunately, since the dose fraction to normal tissue from boron is ten to
fifteen percent, dose assumptions of 12 ppm and 10 ppm produce reasonable estimations
for the time the global maximum would move. This insensitivity to boron concentrations
means the transition times can be calculated at the beginning of the second beam
irradiation, rather than during the transition time. Below is a table showing assumed
boron concentrations for each beam and the resulting fliptime for 96-4.
Table 4.1 Flip times for Subject 96-4
Predicted Data B1 B2 BI B2
Bl (ppm) B2 (ppm) B1 MDRL B1 MDRL B2 MDRL B2 MDRL Predicted Fliptime
15 10 6.556 0.478 0.443 6.330 133.7
12 10 6.401 0.478 0.442 6.330 129.6
15 8 6.556 0.476 0.443 6.207 136.5
12 8 6.401 0.476 0.442 6.207 132.4
10 8 6.247 0.476 0.440 6.207 129.7
15 6 6.556 0.475 0.443 6.084 139.5
12 6 6.401 0.475 0.442 6.084 135.3
10 6 6.247 0.475 0.440 6.084 132.5
Actual Data Actual Fliptime
11.980 8.094 6.369 0.476 0.441 6.213 132.2
Using reasonable approximations for the boron concentrations for each beam, a
reasonable approximation can be made for the fliptime. The current assumptions of 12
and 10 ppm combined with a known beam 1 irradiation time of 128 min would have
predicted a flip time of 129.7 min, within three minutes of the fliptime calculated using
the actual biodistribution data.
A similar retrospective dosimetry analysis of all of the HARVARD/MIT two beam
subjects indicates that the global maximum changed its location for three subjects, as
shown in table 4.2 The ratio of each beam's dose rate to its dose rate at the global
maximum dose rate is an indication of the CGM movement. If the ratio is unity, the
global maximum dose rate is in the same 1 cm3 volume of space as a particular beam's
maximum dose rate.
Table 4.2. Subject Dose Rate Contributions (DCR)
Beam 1 (min) Beam 2 (min) Beam 1 DCR Beam 2 DCR
97-3 132.54 157.03 0.2595 0.9003
97-2 164.69 50.70 0.9886 0.1980
97-1 129.99 126.24 1.0000 0.1000
96-2 132.57 138.23 1.0000 0.0774
96-4 128.02 137.33 0.0693 1.0000
96-3 115.45 139.17 0.0626 1.0000
The above table shows the duration of each beam and the MCNP dose rates and the ratio of each beam's
dose at the MDRL to the dose at the global maximum. This parameter may also be used to gauge the
volume dose.
Table 4.2 indicates several points. For three cases, 97-3, 96-4, and 96-3, the
irradiation was stopped after the global maximum had moved to near the second beam's
global maximum location. In another case, 97-2, the global maximum had started
moving.
Whether the movement of the global maximum is the cause or not, there is a
relation between the movement and the difference between the subject's dose at the end
of irradiation and retrospective dosimetry. As shown in table 4.3, the three largest
overdoses, as determined through retrospective dosimetry, were the three subjects in
which this movement occurred. Although if the movement was the only factor, subject
96-4's dose error would be 3.25 %, indicating other factors, such as changes in the fitting
of the biodistribution curve, influence this error.
Table 4.3 Subject's Dose Estimation
Flip ? Dose Error
97-3 yes 0.82%
97-2 no 0.39%
97-1 no -1.68%
96-2 no -0.62%
96-4 yes 1.16%
96-3 yes 3.23%
The dose error is the difference between retrospective dose and the laptop dose at EOI.
4.4 Chapter Summary
The sequential application of beams will create dynamic dose rates, possibly
changing the location of the global maximum. A retrospective analysis of the BNCT two
beam subjects shows that the global maximum did move to near the second beam's
MDRL in three cases. This movement may explain why these three subjects have the
three largest overdoses of all the two fraction subjects, although other factors, such as an
incomplete biodistribution curve, will also affect the dose calculated at the end of
irradiation. To prevent these overdoses from occurring in the future, it is possible to
calculate when the increase in dose rates will occur. If the second beam irradiation
exceeds this time, the contributions of each beam's maximum to the global maximum
should be determined.
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5. Retrospective Volume Dosimetry Calculations and Effects
Dose volume histograms (DVHs) are important to the medical physicist and
radiation oncologist to determine the therapeutic advantage of the irradiation and to help
relate physical effects with dose distributions",2. The DVH is a plot of how much volume
of tissue receives a specific dose. A specific point indicates that a certain volume has
received the corresponding amount of dose or higher. The DVHs for the Harvard/M.I.T.
MIT subjects can be easily calculated from the dose rates for each voxel, the effective
beam irradiation time, and effective boron concentration. The total dose per voxel can
also be used to calculate the volume averaged dose, another useful value to the radiation
oncologist. An analysis of the volume doses lead to a proposed alternative subject
grouping.
5.1 DVH Calculation
The DVH calculation process is fairly straightforward. The medical physicist
defines the region of interest for neural tissue within MacNCTPlan, just as he did for
tumor. A neural tissue materials file is generated. From within Excel, or other spread
sheet program, each voxel's material is correlated with its total RBE dose, as defined by
the total effective irradiation times and effective boron concentrations for each beam.
Since the fraction of neural tissue is known for each material from the materials file, the
neural tissue volume corresponding to each dose is known. Since MacNCTPlan only
identifies the volume fraction of the ROI in increments of twenty percent3, there are only
five volumes associated with each material and hence dose: 0.2 cm3 , 0.4 cm 3, 0.6 cm3 , 0.8
cm3 and 1 cm3 . For convenience, voxel doses are grouped into 50 cGy dose bins. Using
the Excel histogram data analysis tool, the number of doses in each of the 50 cGy bins is
determined for each of the five fractions. This number is then multiplied by the
corresponding volume contribution for each dose bin to find the total volume associated
with each dose bin. The DVH is the cumulative volume associated with each bin
subtracted from the total volume. An example spread sheet DVH calculation is shown in
Table 5.1.
Table 5.1 DVH Spread Sheet for Subject 97-2.
100% 80% 60% 40% 20% Dose # # # # # Dose Int. DVH
tissue tissue tissue tissue tissue Bins 100% 80% 60% 40% 20% Bin Bin
voxel voxel voxel voxel voxel tissue tissue tissue tissue tissue Vol. Vol.
dose dose dose dose dose voxels voxels voxels voxels voxels
^ 'IO 1.
479 438 365
529 527 389
578 293 426
410 752 455
462 781 280
501 824 304
322 595 335
355 531 365
392 476 243
428 156 262
467 339 294
255 773 322
281 827 231
309 760 262
342 200 556
373 180 616
413 160 658
218 875 611
244 605 506
269 463 441
297 320 393
332 126 435
370 287 171
192 330 302
218 366 713
235 733 760
259 766 828
296 823 748
414
458
494
524
554
323
213
297
509
567
593
263
235
197
361
407
169
187
211
239
275
335
709
926
952
424
290
431
5221 50
100
150
365
400
443
357
209
234
263
717
739
755
637
663
308
334
372
177
342
377
151
645
868
400
443
777
768
206
185
U U U U U
4 7 3.8
27 32 177
3.8
180.8
14 .
1483.8
1306.8
200 128 54 66 26 18 224.8 405.6 1082
250 113 46 57 15 17 193.4 599 888.6
300 97 37 47 26 11 167.4 766.4 721.2
350 77 30 37 22 11 134.2 900.6 587
400 74 19 35 14 14 118.6 1019.2 468.4
450 61 17 25 15 8 97.2 1116.4 371.2
500 59 12 17 8 3 82.6 1199 288.6
550 39 12 11 8 10 60.4 1259.4 228.2
600 35 7 9 7 4 49.6 1309 178.6
650 28 10 6 3 7 42.2 1351.2 136.4
700 31 6 4 2 4 39.8 1391 96.6
750 23 4 3 2 6 30 1421 66.6
800 14 9 3 1 6 24.6 1445.6 42
850 11 7 3 2 5 20.2 1465.8 21.8
900 6 6 3 4 3 14.8 1480.6 7
950 1 2 2 2 9 6.4 1487 0.6
1000 0 0 0 1 1 0.6 1487.6 0
1050 0 0 0 0 0 0 1487.6 0
1100 0 0 0 0 0 0 1487.6 0
1150 0 0 0 0 0 0 1487.6 0
1200 0 0 0 0 0 0 1487.6 0
1250 0 0 0 0 0 0 1487.6 0
Sum 880 321 400 189 176 1487.6
The two bolded columns, dose bins and DVH, form the DVH plot. The five left most columns are an
incomplete listing of all the voxel doses of a particular volume fraction.
Although it is possible to calculate the DVH without using dose bins, it is not possible to
plot with Excel. While other available plotting packages can plot the exact DVH, that amount of
precision is not necessary.
5.2 Dose Volume Histogram Results
Figure 5.1 shows the dose volume histograms for the ten most recent Harvard/MIT BNCT
subjects.
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Figure 5.1 Subject Brain Tissue Dose Volume Histograms
Since the DVH curve is integral dose, the y intercept shows the volume that receives zero
dose or above, i.e. all brain tissue. The calculated volumes could then be compared to known
average data. According to ICRP, the average volume of tissue is 1355 and 1220 for males and
females respectively, based on average density and masses . A more recent head model"'6,
adopted by the MIRD committee as a standard for internal dose calculations, gives a brain tissue
volume of 1467.6 cm3 , in agreement with the calculated volumes obtained here.
The curves show two distinct effects. The low dose regions have dramatic differences in
slopes, which are prescription dose independent but dependent on beam geometry. The curves
for subjects 96-3 and 96-2 even show a plateau region, which results from the greater volume
doses received from a parallel opposed irradiation. The subjects 97-7, 97-6, 97-5, 97-4, were all
single beam irradiations and show the lowest DVHs in the low dose region.
Unlike the low dose region, the high dose region of the DVH is dependent on the
magnitude of the peak dose, as expected. The high dose region is shown below in Fig 5.2
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Figure 5.2 Higher Dose Region DVH
Although it appears that there are volumes of tissue that receive higher than the
prescription dose, this is incorrect. The scaling factors that adjust the MCNP calculations to
experimental data were altered to fit these two cases separately. The highest dose is always the
prescription dose, wherever it is located, and is the x intercept of the DVH curve.
Dose volume histograms can also be generated for the tumors. The method used to
generate neural tissue DVHs, where nearly a thousand cells contribute to the volume dose could
be used, but tumor DVHs can have as few as ten to twenty contributing cells. In this case, the
DVH curve is plotted in response to each individual voxel, rather than a dose bin grouping of
voxels. RBE tumor dose is found for each cell. The doses are then sorted from lowest to highest
and the integral volume is found for each cell, as shown in Table 5.2.
Spread Sheet for Tumor DVH Calculation
Voxel Voxel DVH
Tumor Tumor
Dose Fraction
2343 0.6 0.6
2302 1 1.6
2280 0.4 2
2237 0.6 2.6
2193 0.2 2.8
2184 0.2 3
2174 0.6 3.6
2149 0.4 4
2130 0.2 4.2
2119 1 5.2
2103 0.2 5.4
2075 0.2 5.6
2050 0.6 6.2
2017 0.6 6.8
1991 0.2 7
1973 0.2 7.2
The above table is a complete listing of all voxels containing a tumor fraction of 20% or more.
The corresponding plot to the data shown in Table 5.2, as well as other
Harvard/MIT BNCT subjects, is shown in Figure 5.3.
Table 5.2 Example
100 . 97 -6 C.M. 1065 2169 2344 1973
97-4 G.R. 1065 2661 3082 1907
. 97-3 G.C. 970 2357 2493 2255
97-2 T.T. 970 2415 2772 1426
- 97-1 N.M. 970 2235 3174 1064
80 
- 97-5 I.R. 1065* 1447 2305 733
96-4 J.L. 880 1966 2675 850
96-3 G.M. 880 1881 2379 1217
96-2 S.J. 880 1483 2035 1195
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Figure 5.3 Tumor Dose Volume Histogram
Figure 5.3 shows a variety of effects on the tumor DVH. In addition to beam geometry
effects, the tumor location and extent must be also be considered. Ideally, all of the tumor would
be in a dose region greater than 3000 RBE cGy7. Since the tumors vary in size, location and
extent, the beam geometry and dose cohort have varying effects. Surface tumors will have high
peak and minimum tumor doses, while large tumors could have high peak tumor doses, but low
minimum tumor doses. The peak and minimum tissue and tumor doses are shown the legends of
Figures 5.1, 5.2 and 5.3. The volume averaged dose will be described in section 5.3.
There is a large difference between the tumor DVH and the neural tissue DVH, due to the
increased dose to tumor cells. This increase is caused by the increased concentration of BPA in
tumor cells, by a factor of 3.5 times that of normal tissue. The RBE of boron dose is increased to
3.8 for tumor from 1.35 for normal tissue. When the tumor and tissue DVH are combined, the
therapeutic advantage is shown more clearly, as indicated by the arrow in Figure 5.4.
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Figure 5.4 Tumor and Tissue DVHs. All volumes are expressed in terms of their relative percentage.
5.3 Volume Averaged Dose
Another clinically important value is the volume averaged dose. Both the tumor and brain
volume dose can be calculated as the sum of all tumor or brain voxel doses, D(i), times their
associated tumor or brain volume, V(i), divided by the total tumor or brain volume, as shown in
Equation 5.1
i = i1025
I D(i) -V(i)
i=l
Volume Average Dose = Equation 5.2
i = 11025
1 V(i)
i=l
While equation 5.2 is a sum over all voxels, only one to two thousand voxels have non zero
volume fractions of brain. Typically one hundred voxels have non zero volume fractions of
tumor.
Using equation 5.2, the volume averaged tumor and tissue doses were calculated for the
Harvard / M.I.T. BNCT subjects, listed in figures 5.1, 5.2 and 5.3.
5.4 Relation to Peak Dose
For all of the above subjects, except 97-4 and 97-5, two beams were used. The
second beam, in addition to making a contribution to the global maximum, increases the
volume dose. One measure of how the beams combine is the ratio of the dose at a
particular beam's maximum to the dose at the global maximum. For example, if two
beams of equal irradiation times are very close, the global maximum would be in the
vicinity of each beam's maximum, and the above ratio would be very close to unity, as
illustrated in figure 5.5.
Beam 1 Beam 2
Beam 1 MDL 00 Beam 2 MDL
Post Irradiation Global Max
Figure 5.5 Dual Irradiation with close entry locations.
In this case, only small volumes of tissue would receive high doses when the
global maximum reaches the prescription dose. For nearly opposed beams, the global
maximum will be close to either beam's maximum, which are widely separated, as shown
in figure 5.6. Thus one ratio would be close to unity and the other will be close to zero.
Locations of the Maximum
Dose from Individual Beams
Beam 1 Beam 2
Post Irradiation Global Max
Figure 5.6 Dual Beam Irradiation with distant entry locations.
Since the second beam is depositing more of its energy in the region of its
maximum, rather than the global maximum, much larger volumes receive a higher dose.
This effect can be seen in the above DVH for doses ranging from 200 to 650 cGy. The
subjects' maximum dose ratios are shown in table 5.3, sorted by decreasing value of the
second beams contribution.
Table 5.3 Subject Max Dose Ratios
Beam 1 Beam 2
97-3 0.2595 0.9003
97-2 0.9886 0.1980
97-1 1.0000 0.1000
96-4 0.0693 1.0000
96-3 0.0626 1.0000
97-5 1 -
97-4 1 -
According to the above chart, 96-4 and 97-1 should have similar high dose curves,
and 97-3 and 97-2. 97-1 should be between those two groups. Unfortunately, only 96-4
and 97-1 grouping are correct.
5.5 Proposed Grouping
If the volume averaged tissue dose is considered to be the representative quantity
for a dose cohort group, rather than the peak dose, a new grouping results. While the
cohort groups will still be defined in accordance to the peak tissue dose, as required by
the protocol, this new grouping provides an alternative way to evaluate the data. The
proposed groupings are listed in table 5.4, while the subject volume doses are plotted in
Figure 5.5
Table 5.4 Proposed Subject Dose Cohorts
BNCT Vol Averaged 4 Proposed Groups 2 Proposed Groups
Subject Tissue Dose Group Avg Deviation % Increase Group Avg Deviation % Increase
RBE cGy RBE cGy RBE cGy RBE cGy RBE cGy
96-2 511 493 25.7 14.4
96-3 474
96-4 448 455 37.9 48.3
97-3 424 431 15.6 30.3
97-1 419
97-2 343 331 17.2 13.4
97-4 318
97-7 303 307 25.2
97-6 296 291 14.3
97-5 275
The two
groups.
600
500 -
400 -
proposed grouping methods, with group average doses and the amount of increase between
96-2 96-3 96-4 97-1 97-2 97-3 97-4 97-5 97-6 97-7 97-5
Subject #
Figure 5.7 Subject Volume Doses
Figure 5.7 illustrates an important point. Even though the peak dose increases
with increasing subject number, the volume doses can decrease. The recent subjects have
been treated with single beam applications which have lower volume doses than the dual
beam irradiations.
5.6 Peak Tissue Dose vs. Peak Brain Dose
The final value of possible clinical significance calculated for this thesis is the
peak brain dose. This value is important when comparing data to other BNCT clinical
trials. While the peak dose to tissue is a calculation based on phantom measurements, its
location is not measured when multiple irradiation beams are applied. Using the
calculated voxel doses, the peak dose to any voxel containing 20% or more neutral tissue
or tumor can be found. The peak tissue, brain and tumor doses for the Harvard/MIT
subjects are shown in Table 5.5.
Table 5.5 Peak Doses to Various Tissues
Prescription Peak Peak Neural Peak
Subject Dose Tissue Dose Tissue Dose Tumor Dose
97-7 1065 1088 1020 3166
97-6 1065 1105 1042 2344
97-4 1065 1153 989 3082
97-3 970 983 933 2493
97-2 970 992 830 2772
97-1 970 959 959 3174
97-5 1065* 909 830 2305
96-4 880 891 889 2675
96-3 880 908 843 2379
96-2 880 875 875 2035
Subject 97-5 was originally placed in the 1065 prescription dose cohort, but the second irradiation beam
was not completed.
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6. Conclusions
This thesis contains improvements to the Harvard/MIT BNCT treatment process
in three distinct areas. The treatment planning calculations were reduced in time, the
dosimetry procedure during irradiation was increased in accuracy, and the retrospective
volume dosimetry was calculated. A summary of the current steps in treatment and
treatment planning is included.
As a result of this thesis work, the Harvard/MIT BNCT treatment planning
calculations were considerably reduced, from two hours thirty minutes to fifty nine
minutes for a single beam scoping calculation. This wall clock runtime reduction is from
enhancements to the Monte Carlo program, MCNP4B, and utilization of parallel
calculations (i.e. PVM) on a network of linked computers. A voxel dose rate analysis
was performed to see if the run times could be lowered by running fewer particles, but it
indicated that an appropriate number of particles were currently being run.
While the decrease in runtimes for a single beam is significant, typically the dose
rates for four or five irradiation beams are calculated. A brief investigation into the total
runtime reduction of all five beams showed that until the number of linked computers
exceeds the number of potential beams, these calculations should not be performed in
parallel. While PVM is not immediately applicable for these treatment planning
calculations on two computers, the anticipated purchase of several high end computers
will use this technology to reduce the calculation time to minutes, allowing the iterative
approach currently used in conventional radiotherapy to be used.
During this thesis research, the previously unnoticed phenomenon of peak dose
location movement was recognized and investigated. This movement has a direct effect
on the calculations that determine the delivered peak dose to the subject during
irradiation, creating the possibility of underestimation of peak dose, thus subject
overdose. While the investigated cases had less than 5% overdose, the potential exists for
higher overdoses. For beams that are parallel opposed, this movement would cause a
tenfold increase in dose rate to the peak dose location. Further investigation led to a
prediction of when this movement would occur, and how to avoid its potential overdoses.
The calculation of volumetric dosimetry is useful for the radiation oncologist to
relate the radiation damage and dose. The dose volume histograms, volume averaged
dose, peak and minimum dose to soft tissue, brain tissue, and tumor were calculated. The
DVHs illustrate the how different beam orientations and combinations can affect the dose
distributions. Based on the volume averaged doses, an alternative subject grouping was
proposed.
Appendix A
Appendix A includes a description of the failed attempts to install MCNP and
PVM on various operating systems.
A. 1 Windows
The operating systems Microsoft Windows NT and Microsoft Windows 95 are
popular operating systems used on PC's. Adapting MCNP4B for use with PVM on these
systems would greatly increase the number of computers available for addition to the
parallel virtual machine, with minimal effort to reconfigure the system. Running MCNP
in parallel on these systems had not been attempted previously.
Several problems were initially encountered. MCNP is a complex program
requiring a well written compiler to create an executable that will pass the test suite.
Lahey makes two such compilers, FORTRAN 77 (F77) and FORTRAN 90 (F90). The
Lahey FORTRAN 77 was officially supported for the release of MCNP4A. FORTRAN
90 was tested and found to create an executable that is about ten percent faster than the
executable created by Lahey F77.
Incorporation of the PVM libraries required a linker that would be able to read
both the F77 object code and the PVM libraries, created by Microsoft C++. The Lahey
and Microsoft object files and libraries were incompatible. Either PVM or MCNP would
have to switch to a compatible compiler. Several tests were performed to identify
compatible compilers. Three were found, although others may exist: Watcom C++ and
Watcom FORTRAN, Microsoft FORTRAN Powerstation and Microsoft Visual C++, and
Lahey FORTRAN and Metaware High C. Watcom FORTRAN would not compile the
MCNP source code without extensive modifications. During testing, Microsoft
FORTRAN Powerstation was acquired by Digital Equipment Corp., (DEC), who began
offering their DEC Visual FORTRAN for Windows. It was able to compile MCNP with
minor revisions because MCNP had already been ported to DEC operating systems,
which use a similar DEC compiler. The DEC FORTRAN linker was able to read the
PVM libraries, and create a parallel version of MCNP, mcnp.pvm.
PVM for windows was installed in a similar manner as on Linux. Networked NT
computers were linked together and successfully ran the PVM test executable "hello".
Mcnp.pvm would start on other linked NT's, but they would not run.
A.2 MkLinux
In addition to the work on PC's, the linking of Macintosh computers to the virtual
machine was investigated. The treatment planning software, MacNCTPlan is used on
Power Macintosh computer, which would be convenient to link. Apple Computer ported
the Linux kernel, called MkLinux for its Power Macintosh computers, making it
exceptionally easy to install. Another port of Linux for Macintosh is Linux-pmac,
supposedly faster than Apple's MkLinux, but more complicated to install.
The installation of MkLinux is handled by a Mac program, InstallMkLinux, which
guides the user step by step through reconfiguring the system and installing MkLinux.
The MkLinux operating system is well integrated with MacOS, providing a simple "boot
MkLinux" button when the system starts. The most challenging part of the MkLinux
installation, and any other Linux installation, was repartitioning the hard drive to create
500 megabytes or more of free space. After this was done with the program, pdisk,
provided with InstallMkLinux, the computer was rebooted.
MkLinux was able to recognize all SCSI devices, including the SCSI CDROM,
which allowed convenient installation of MCNP. Apple's MkLinux release also included
the FORTRAN and C compilers, GNU G77 and GNU GCC, necessary to compile
MCNP. Following the same procedure used for installing MCNP on a Linux computer,
MCNP was compiled and linked on MkLinux. The test suite indicated several rounding
errors, considered acceptable, and two tracking errors. The tracking errors indicate
potential problems with the compiler or operating system. MCNPBNCT was able to run
a BNCT treatment planning problem, but since this run was too slow to be useful, its
results were not verified. One of the main drawbacks of the MkLinux installation was the
failure of its networking capabilities.
A.3 Linux-pmac
Another Linux based operating system, Linux-pmac, which had functional
networking utilities, was installed on the same machine. Linux-pmac installation is
conveniently managed by Red Hat, so once a simple boot disk is created, Linux-pmac can
be installed via ftp. Although Linux-pmac's GNU G77 could not compile MCNP4B, it
did recognize and execute the MkLinux MCNPBNCT executable. It also supported full
networking capabilities.
From within the Linux-pmac operating system, PVM was obtained via ftp and
installed. The Linux-pmac GNU GCC did compile PVM and the associated libraries.
The computer was added to a virtual machine consisting of the Sager laptop and an MIT
SGI Indigo computer. The PVM hello program worked appropriately, indicating the
functionality of the virtual machine. MCNP was recompiled and linked with the PVM
libraries in MkLinux to create "mcnp.pvm". Although the master MCNP executable was
able to start subtasks on the Linux-pmac machine, they did not continue running. The
Linux-pmac job running MCNP in parallel, like the Windows job, was unable to
successfully complete.
A.4 Other Possibilities
Although none of the above trials was successful, several other options do exist.
The GNU tools have been ported to the Windows operating systems, possibly allowing
an installation similar to that of Linux. Other Linux and UNIX operating systems exist
for the Macintosh, such as the Mach-Ten UNIX emulator. Additionally, all of these
programs are occasionally upgraded, perhaps correcting some of the deficiencies
encountered.
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